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Abstract: Danusertib (Danu) is a pan-inhibitor of Aurora kinases and a third-generation breakpoint 
cluster region-Abelson murine leukemia viral oncogene homolog 1 (Bcr-Abl) tyrosine kinase 
inhibitor, but its antitumor effect and underlying mechanisms in the treatment of human breast 
cancer remain elusive. This study aimed to investigate the effects of Danu on the growth, apopto-
sis, autophagy, and epithelial-to-mesenchymal transition (EMT) and the molecular mechanisms 
in human breast cancer MCF7 and MDA-MB-231 cells. The results demonstrated that Danu 
remarkably inhibited cell proliferation, induced apoptosis and autophagy, and suppressed EMT 
in both breast cancer cell lines. Danu arrested MCF7 and MDA-MB-231 cells in G
2
/M phase, 
accompanied by the downregulation of cyclin-dependent kinase 1 and cyclin B1 and upregula-
tion of p21 Waf1/Cip1, p27 Kip1, and p53. Danu significantly decreased the expression of B-cell 
lymphoma-extra-large (Bcl-xl) and B-cell lymphoma 2 (Bcl-2), but increased the expression of Bcl-
2-associated X protein (Bax) and p53-upregulated modulator of apoptosis (PUMA), and promoted 
the cleavage of caspases 3 and 9. Furthermore, Danu significantly increased the expression levels 
of the membrane-bound microtubule-associated protein 1A/1B-light chain 3 (LC3-II) and beclin 
1 in breast cancer cells, two markers for autophagy. Danu induced the activation of p38 mitogen-
activated protein kinase (MAPK) and extracellular signal-regulated kinases 1 and 2 (Erk1/2) 
and inhibited the activation of protein kinase B (Akt)/mammalian target of rapamycin (mTOR) 
signaling pathways in breast cancer cells. Treatment with wortmannin (a phosphatidylinositol 
3-kinase inhibitor) markedly inhibited Danu-induced activation of p38 MAPK and conversion 
of cytosolic LC3-I to membrane-bound LC3-II. Pharmacological inhibition and small interfering 
RNA-mediated knockdown of p38 MAPK suppressed Akt activation, resulting in LC3-II accumu-
lation and enhanced autophagy. Pharmacological inhibition and small interfering RNA-mediated 
knockdown of Erk1/2 also remarkably increased the level of LC3-II in MCF7 cells. Moreover, 
Danu inhibited EMT in both MCF7 and MDA-MB-231 cells with upregulated E-cadherin and zona 
occludens protein 1 (ZO-1) but downregulated N-cadherin, zinc finger E-box-binding homeobox 
1 (TCF8/ZEB1), snail, slug, vimentin, and β-catenin. Notably, Danu showed lower cytotoxicity 
toward normal breast epithelial MCF10A cells. These findings indicate that Danu promotes cel-
lular apoptosis and autophagy but inhibits EMT in human breast cancer cells via modulation of 
p38 MAPK/Erk1/2/Akt/mTOR signaling pathways. Danu may represent a promising anticancer 
agent for breast cancer treatment. More studies are warranted to fully delineate the underlying 
mechanisms, efficacy, and safety of Danu in breast cancer therapy. 
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Introduction
Breast cancer is a major health issue worldwide and has been considered as the second 
most common cancer and the most common cause of cancer-related death in women 
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worldwide, with 521,000 deaths in 2012.1,2 It is placing a 
heavy burden on individuals, families, and society.1,2 In the US, 
breast cancer is the most common cancer and the second most 
common cause of cancer-related death among women.3 There 
were 220,097 women and 2,078 men who were diagnosed with 
breast cancer, and there were 40,931 women and 443 men who 
died from breast cancer in 2011.4 Similarly, breast cancer is the 
most common and the leading cause of cancer-related death in 
women in the People’s Republic of China. In 2008, there were 
about 169,000 new cases of breast cancer, and 44,900 deaths 
resulted from breast cancer among women in the People’s 
Republic of China.2 The primary modalities for breast cancer 
therapy include surgery, radiation therapy, chemotherapy, 
hormone therapy, immunotherapy, and targeted therapy, which 
are applied alone or more often in combination.5 These breast 
cancer therapies aim to remove tumor tissue/burden or induce 
cancer cell death involving necrosis, senescence, autophagy, 
and mitotic catastrophe.6 However, currently used chemo-
therapy for breast cancer is often accompanied with side effects 
and drug resistance, resulting in therapeutic failure in breast 
cancer patients. Thus, there is an urgent need to identify and 
develop new agents with reduced side effects and improved 
efficacy for breast cancer treatment. 
Mitosis is a critical step in the proliferation of cells involv-
ing several checkpoint systems controlling key steps of the 
process. Abnormalities in mitosis have been implicated in the 
initiation, development, and progression of cancer. Drugs that 
are capable of managing the abnormal progression of mitosis 
are currently being tested in cancer therapy.7 Aurora kinases, 
a class of centrosomal serine/threonine kinase involved in 
cell division, play a pivotal role in chromosome segregation 
during the process of cell division through the formation of 
bipolar spindles. There are three types of Aurora kinases in 
mammals, namely Aurora A, B, and C (AURKA/B/C). They 
are structurally and functionally different, and have differ-
ent intracellular locations. The human AURKA is located on 
chromosome segment 20q13, which is often amplified and/
or overexpressed in several human epithelial malignancies, 
including colon carcinoma, lymphoma, gastrointestinal 
adenocarcinomas, breast cancer, and bladder cancer.8–12 
AURKB, known as the chromosomal passenger protein, is 
essential for accurate chromosome segregation and cytokine-
sis.13 Aberrant expression of AURKA and AURKB has been 
implicated in the initiation, development, and progression of 
a wide range of malignancies,14–17 which renders AURKA and 
AURKB to be potential therapeutic targets for cancer treat-
ment through inhibiting their activities and/or expression. 
Currently, there are a number of Aurora kinase inhibitors 
in different stages of preclinical and clinical development. 
Danusertib (Danu) is a pan-inhibitor of Aurora kinases and 
a third-generation breakpoint cluster region-Abelson murine 
leukemia viral oncogene homolog 1 (Bcr-Abl) tyrosine kinase 
inhibitor. It potently inhibits the activities of AURKA/B/C, 
with the half maximal inhibitory concentration (IC
50
) value 
of 13, 79, and 61 nM, respectively.18 Recently, Danu has 
been studied in Phase I and II trials, showing great thera-
peutic potential in the treatment of a wide range of cancers, 
including both advanced solid tumors and leukemias.18,19 The 
clinical anticancer activity of Danu has largely been consis-
tent with its cytostatic effects. The best tumor response was 
stable disease which was observed in about 23.7% of patients 
with advanced or metastatic solid tumors.20 However, the 
effect and underlying mechanisms of Danu in breast cancer 
treatment have not yet been determined. In the present study, 
we investigated the effects of Danu on the proliferation, cell 
cycle distribution, apoptosis, autophagy, and epithelial-to-
mesenchymal transition (EMT) in breast cancer cells, and 
explored the possible mechanisms responsible for the anti-
cancer effect of Danu in breast cancer cells. 
Materials and methods
chemicals and reagents
Danu, previously known as PHA-739358 (N-[5-[(2R)-2-
methoxy-2-phenylacetyl]-4,6-dihydro-1H-pyrrolo[3,4-c]
pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide) 
(Figure 1A), RNase A, propidium iodide (PI), thiazolyl blue 
tetrazolium bromide (MTT), Dulbecco’s phosphate-buffered 
saline (D-PBS), protease inhibitor and phosphatase inhibitor 
cocktails, 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic 
acid (HEPES), ethylenediaminetetraacetic acid (EDTA), and 
fetal bovine serum (FBS) were purchased from Sigma-Al-
drich Co. (St Louis, MO, USA). Dulbecco’s Modified Eagle’s 
Medium (DMEM)/F12 (1:1) and Roswell Park Memorial 
Institute (RPMI) 1640 medium were purchased from Corn-
ing Life Sciences Inc. (Manassas, VA, USA). Lipofectamine 
2000, 6-diamidino-2-phenylindole (DAPI), and Opti-mini-
mal essential medium (MEM) were bought from Thermo 
Fisher Scientific Inc. (Waltham, MA, USA). The annexin 
V:phycoerythrin (PE) apoptosis kit was purchased from BD 
Biosciences Inc. (San Jose, CA, USA). Cyto-ID® Autophagy 
detection kit was obtained from Enzo Life Sciences Inc. 
(Farmingdale, NY, USA). The polyvinylidene difluoride 
(PVDF) membrane was bought from EMD Millipore Inc. 
( Billerica, MA, USA). Western blotting substrate and Pierce™ 
bicinchoninic acid (BCA) protein assay kit were bought from 
Thermo Scientific Inc. (Hudson, NH, USA). Bafilomycin 
A1 (a known inhibitor of the late phase of autophagy, which 
prevents the maturation of autophagic vacuoles by inhibiting 
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fusion between autophagosomes and lysosomes), wortman-
nin (WM, an irreversible and selective phosphatidylinositol 
3-kinase [PI3K] inhibitor and a blocker of autophagosome 
formation), and SB202190 (an autophagy inducer and spe-
cific p38 mitogen-activated protein kinase [MAPK] inhibitor) 
were purchased from Invivogen Inc. (San Diego, CA, USA). 
U0126 (a specific extracellular signal-regulated kinases 1 
and 2 [Erk1/2] inhibitor) was purchased from Santa Cruz 
Biotechnology Inc. (Dallas, TX, USA). The negative control 
small interfering RNA (siRNA), p38 MAPK siRNA, and 
p44/42 MAPK (Erk1/2) siRNA, and primary antibodies 
against human p53, p21 Wafl/Cipl, p27 Kipl, cyclin B1, 
cyclin dependent kinase 1 (CDK1)/cell division cycle pro-
tein 2 (CDC2), CDK2, the p53-upregulated modulator of 
apoptosis (PUMA), B-cell lymphoma 2 (Bcl-2), Bcl-2-like 
protein 4/Bcl-2-associated X protein (Bax), B-cell lymphoma 
extra-large (Bcl-xl), cleaved caspase 3, cleaved caspase 9, 
microtubule-associated protein 1A/1B-light chain 3 (LC3-I), 
LC3-II, p38 MAPK, phosphorylated (p) p38 MAPK at 
Thr180/Tyr182, Erk1/2, p-Erk1/2 at Thr202/Tyr204, pro-
tein kinase B (Akt), p-Akt at Ser473, mammalian target 
of rapamycin (mTOR), p-mTOR at Ser2448, beclin 1, and 
EMT antibody sampler kit (No 9782) were all purchased 
from Cell Signaling Technology Inc. (Beverly, MA, USA). 
The EMT antibody sampler kit contains primary antibodies 
to N-cadherin, E-cadherin, zona occludens protein 1 (ZO-1), 
vimentin, slug, snail, zinc finger E-box-binding homeobox 1 
(TCF8/ZEB1), and β-catenin. The antibody against human 
β-actin was obtained from Santa Cruz Biotechnology Inc. 
cell lines and cell culture
MCF7 and MDA-MB-231 cells are the epithelial breast 
cancer cell lines, and MCF10A is the normal breast epithelial 
cell line. MCF-10A cells are often used as a normal control 
in breast cancer studies. These cells are derived from the 
mammary tissue of a cystic fibrosis patient and show nor-
mal mammary epithelial cell morphology. These cells do 
not have mutations in the p53 gene but show homozygous 
loss of the p16/p15 locus and do not form tumors in nude 
mice or colonies in semi-solid low melting agarose. MCF7, 
MDA-MB-231, and MCF10A cells were all obtained from 
American Type Culture Collection (Manassas, VA, USA). 
MCF7 and MDA-MB-231 cells were maintained in RPMI 
1640 medium supplemented with heat-inactivated 10% FBS 
and 1% penicillin/streptomycin. MCF10A cells were grown 
in DMEM/F12 (1:1) supplemented with 5% horse serum, 
10 µg/mL insulin, 100 ng/mL cholera enterotoxin, 0.5 mg/
mL hydrocortisone, and 20 ng/mL epidermal growth factor. 
All cells were maintained in a 5% CO
2
/95% air-humidified 
incubator at 37°C. Danu was dissolved in dimethyl sulfoxide 
(DMSO) with a stock concentration of 25 mM and freshly 
diluted to the predetermined concentrations with culture 
medium, with the final concentration of DMSO at 0.05% 
(v/v). The control cells received the vehicle only.
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Figure 1 The chemical structure and the cytotoxic effects of Danu on malignant and nonmalignant breast epithelial cells for 24 and 48 hours.
Notes: cytotoxicity of Danu toward McF10a, McF7, and MDa-MB-231 cells was determined by the MTT assay. (A) The chemical structure of Danu. Percentage viability 
of McF10a, McF7, and MDa-MB-231 cells when treated with Danu for (B) 24 and (C) 48 hours at concentrations of 0.01, 0.1, 1, 5, and 20 µM.
Abbreviations: Danu, danusertib; conc, concentration; ic50, half maximal inhibitory concentration.
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cell viability assay 
The effect of Danu on cell viability was examined using the 
MTT assay. Briefly, cells were seeded in 96-well culture plates 
at a density of 8×103 cells/well. After cells were attached, the 
cells were treated with Danu at different concentrations ranging 
from 0.01 µM to 20 µM. The concentration of DMSO was at 
0.05% (v/v). The control cells received the vehicle only. After 
24- or 48-hour incubation, 10 µL MTT (5 mg/L) was added to 
each well and cultured for a further 4 hours. Then, solution was 
removed and 150 µL DMSO was added to dissolve the crystal. 
The absorbance was measured at a wavelength of 490 nm 
using a Synergy™ H4 Hybrid microplate reader (BioTek Inc., 
Winooski, VT, USA). The half maximal inhibitory concentra-
tion (IC
50
) values were determined using the relative viability 
over Danu concentration curve.
cell cycle distribution analysis 
The effect of Danu on cell cycle distribution was examined 
using PI as a DNA stain to determine DNA content by flow 
cytometry, as described previously.21 Briefly, MCF10A, 
MCF7, and MDA-MB-231 cells were treated with Danu 
at concentrations of 0.01, 0.1, and 0.5 µM for 24 hours. In 
separate experiments, MCF10A, MCF7, and MDA-MB-231 
cells were treated with 0.5 µM Danu for 4, 8, 12, 24, 48, and 
72 hours. Following the Danu treatment, cells were detached, 
washed by D-PBS, centrifuged, and fixed in 70% ethanol 
at -20°C overnight. Then, the cells were resuspended in 
1 mL of PBS containing 1 mg/mL RNase A and 50 µg/
mL PI. Cells were incubated in the dark for 30 minutes at room 
temperature. The cells were subjected to cell cycle analysis 
using a flow cytometer (Becton Dickinson Immunocytometry 
Systems, San Jose, CA, USA). The flow cytometer collected 
10,000 events for analysis.
Quantification of cellular apoptosis
Apoptotic cells were quantitated using the annexin V:PE 
apoptosis detection after cells were treated with Danu at 
concentrations of 0.01, 0.1, and 0.5 µM for 24 hours, as 
described previously.21 Briefly, cells were trypsinized and 
washed twice with cold PBS, and then resuspended in 1× 
binding buffer with 2.5 µL of annexin V:PE and 2.5 µL of 
7-amino-actinomycin D (7-AAD, used as a nucleic acid dye) 
at 1×105 cells/mL in a total volume of 100 µL. The cells were 
gently mixed and incubated in the dark for 15 minutes at 
room temperature. A quota of 1× binding buffer (400 µL) was 
then added to a clean test tube and the number of apoptotic 
cells was quantified using a flow cytometer within 1 hour. 
Cells that stain positive for annexin V:PE and negative for 
7-AAD are undergoing apoptosis; cells that stain positive 
for both annexin V:PE and 7-AAD are either in the endstage 
of apoptosis, are undergoing necrosis, or are already dead; 
cells that stain negative for both annexin V:PE and 7-AAD 
are alive and not undergoing apoptosis.
Quantification of cellular autophagy
MCF10A, MCF7, and MDA-MB-231 cells were treated with 
fresh medium alone, control vehicle alone (0.05% DMSO, 
v/v), or Danu (0.01, 0.1, and 0.5 µM) for 24 hours at 37°C. In 
separate experiments, MCF10A, MCF7, and MDA-MB-231 
cells were treated with 0.5 µM Danu for 4, 8, 12, 24, 48, and 
72 hours. To investigate the mechanisms for Danu-induced 
autophagy, cells were pretreated with 10 µM WM (a PI3K 
inhibitor and autophagy blocker), 10 µM bafilomycin A1 (an 
autophagy inhibitor), 10 µM SB202190 (a selective inhibi-
tor of p38 MAPK), or 10 µM U0126 (a selective inhibitor of 
Erk1/2) for 30 minutes in MCF7 and MDA-MB-231 cells, 
then co-treated with 0.5 µM Danu for a further 24 hours. 
Groups of cells treated with each of these compounds alone 
were also included. All inhibitors were dissolved in DMSO at 
a final concentration of 0.05% (v/v). Cells were resuspended 
in 250 µL of phenol red-free culture medium (Thermo Fisher 
Scientific Inc.; No: 1294895) containing 5% FBS, and 250 µL 
of the diluted Cyto-ID® Green stain solution was added to each 
sample and mixed well. Cyto-ID® Green stain is a cationic 
amphiphilic tracer that selectively labels autophagic vacuoles 
in cells. Cells were incubated for 30 minutes at 37°C in the 
dark, collected by centrifugation, washed with 1× assay buffer, 
and resuspended in 500 µL fresh 1× assay buffer. Cells were 
subjected to flow cytometric analysis using the green (FL1) 
channel. The flow cytometer collected 10,000 events.
rna interference
siRNA for silencing gene expression was performed by 
transfection of RNA oligonucleotides with lipofectamine 
2000 according to the manufacturer’s instructions. MCF7 
cells were transfected with the negative control siRNA, 
p38 MAPK siRNA, or Erk1/2 siRNA in Opti-MEM, using 
lipofectamine 2000. After incubation for 4 hours, the Opti-
MEM™ medium was replaced with complete medium 
containing 10% FBS. The cells were then incubated for an 
additional 48 hours and treated with Danu. The cell samples 
were collected for further analysis. 
Western blotting analysis
The expression levels of cellular proteins of interest were 
determined using Western blotting assays. MCF10A, 
MCF7, and MDA-MB-231 cells were washed with pre-
chilled PBS after 24-hour treatment with Danu at 0.01, 
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0.1, and 0.5 µM, lysed with the radioimmunoprecipitation 
assay (RIPA) buffer containing the protease inhibitor and 
phosphatase inhibitor cocktails, and centrifuged at 3,000× 
g for 10 minutes at 4°C. Protein concentrations were mea-
sured using a Pierce™ BCA protein assay kit. Subsequently, 
equal amounts of protein samples (30 µg) were resolved 
by 4× sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) sample loading buffer and electro-
phoresed on 7%–12% SDS-PAGE mini-gel after thermal 
denaturation at 95°C for 5 minutes. Then, proteins were 
transferred onto methanol-activated PVDF membrane at 
400 mA for 2 hours at 4°C. Membranes were blocked with 
5% skim milk for 1 hour at room temperature, probed with 
the primary antibody overnight at 4°C, and then blotted with 
respective secondary anti-mouse or anti-rabbit antibody. 
Visualization was performed using Bio-Rad ChemiDoc™ 
XRS (Hercules, CA, USA) with enhanced-chemilumines-
cence substrate, and the blots were analyzed using Image 
Lab 3.0 (Bio-Rad). The matching densitometric value of the 
internal control β-actin was used to normalize the protein 
expression level. 
statistical analysis
Data are expressed as the mean ± standard deviation (SD). 
Comparisons of multiple groups were performed using one-
way analysis of variance (ANOVA) followed by Tukey’s 
multiple comparison procedure. Values of P0.05 were 
considered statistically significant. Assays were performed 
at least three times independently.
Results
Danu shows significantly higher 
cytotoxicity toward breast cancer cells 
than normal breast epithelial cells
In order to evaluate the cytotoxicity of Danu, we used the 
MTT assay to measure the inhibitory effect of Danu on 
the proliferation of malignant MCF-7 and MDA-MB-231 
cells, and nonmalignant MCF10A cells. The concentration-
 dependent inhibitory effects of Danu on the growth of 
MCF10A, MCF7, and MDA-MB-231 cells are shown in 
Figure 1B and C. MCF10A, MCF7, and MDA-MB-231 
cells were exposed to Danu for 24 or 48 hours at different 
concentrations. When MCF10A cells were treated with Danu 
at 0.01, 0.1, 1, 5, and 20 µM for 24 hours, the percentage of 
cellular viability over the control cells (100%) was 96.1%, 
88.9%, 73.9%, 55.4%, and 47.9%, respectively; the IC
50
 value 
of 24-hour Danu treatment was 27.15 µM. The percentage of 
live MCF7 cells over the control cells (100%) was 77.2%, 
71.9%, 55.5%, 39.7%, and 32.2%, respectively. The IC
50
 
value of 24-hour treatment was 9.10 µM. The percentage of 
live MDA-MB-231 cells over the control cells (100%) was 
66.3%, 58%, 41.6%, 33.9%, and 26.6%, respectively; the IC
50
 
value of 24-hour treatment was 4.16 µM (Figure 1B). When 
MCF10A cells were treated with Danu at 0.01, 0.1, 1.0, 5.0, 
and 20 µM for 48 hours, the percentage of cellular viability 
over the control cells (100%) was 96.6%, 89.9%, 72.1%, 
50.1%, and 33.6%, respectively; the IC
50
 value of 48-hour 
treatment was 25.47 µM. The percentage of live MCF7 cells 
over the control cells (100%) was 63.9%, 56.1%, 53.1%, 
39.8%, and 33.8%, respectively; the IC
50
 value of 48-hour 
treatment was 5.14 µM. The percentage of live MDA-MB-
231 cells over the control cells (100%) was 55.9%, 48.5%, 
44.3%, 39.5%, and 26.4%, respectively; the IC
50
 value of 
48-hour treatment was 3.09 µM (Figure 1C). These results 
indicate that Danu induces concentration-dependent inhibi-
tory effects on the growth of MCF10A, MCF7, and MDA-
MB-231 cells, but that the cytotoxic effect of Danu is much 
lower in normal MCF10A cells than that in both malignant 
cell lines.
Danu induces g2/M arrest in breast 
cancer cells
Since we have observed an inhibitory effect on cell growth, 
we further assessed the effect of Danu on the cell cycle 
distribution of MCF10A, MCF7, and MDA-MB-231 cells by 
flow cytometry. Treatment of MCF10A, MCF7, and MDA-
MB-231 cells with Danu arrested cells in G
2
/M phase in a 
concentration- and time-dependent manner. At basal level, 
the percentage of MCF10A, MCF7, and MDA-MB-231 cells 
in G
2
/M phase was 28.3%, 21.4%, and 25.9%, respectively. 
As shown in Figure 2A and B, there was a significant increase 
in the cell number in G
2
/M phase in MCF10A, MCF7, and 
MDA-MB-231 cells after incubation with Danu at 0.5 µM 
for 24 hours. The percentage of cells arrested in G
2
/M phase 
was 70.8%, 69.1%, and 80.6% in MCF10A, MCF7, and 
MDA-MB-231 cells, respectively. This gave an increase 
of 1.5-, 2.2-, and 2.1-fold, respectively, compared to the 
control cells treated with DMSO only (P0.001 by one-
way ANOVA; Figure 2B). The increase in magnitude of the 
number of malignant breast cells in G
2
/M phase was 1.4- and 
1.5-fold higher than that in normal breast epithelial cells. 
However, a lower concentration of Danu (0.01 and 0.1 µM) 
did not significantly affect the number of MCF10A, MCF7, 
and MDA-MB-231 cells (P0.05 by one-way ANOVA; 
Figure 2B). Treating MCF10A, MCF7, and MDA-MB-231 
cells with Danu at 0.5 µM also significantly affected the 
number of cells in G
1
 phase. The number of cells in G
1
 phase 
was significantly reduced by 60.5%, 63.3%, and 77.3% in 
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Figure 2 Danu induces cell cycle arrest in McF10a, McF7, and MDa-MB-231cells.
Notes: cells were treated with Danu at 0.01, 0.1, and 0.5 µM for 24 hours and then subjected to flow cytometric analysis. (A) Representative DNA fluorescence histograms 
of Pi-stained McF10a, McF7, and MDa-MB-231 cells, and (B) the bar graphs showing the percentage of McF10a, McF7, and MDa-MB-231 cells in g1, s, and g2/M phases. 
Data are expressed as the mean ± sD of three independent experiments. ***P0.001 by one-way anOVa.
Abbreviations: Danu, danusertib; conc, concentration; sD, standard deviation; anOVa, analysis of variance; Pi, propidium iodide; Dip, diploid.
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MCF10A, MCF7, and MDA-MB-231 cells treated with Danu 
at 0.5 µM, respectively (P0.001 by one-way ANOVA; 
Figure 2B). 
We further conducted separate experiments to evaluate 
the effect of Danu treatment at 0.5 µM on the cell cycle 
distribution of MCF10A, MCF7, and MDA-MB-231 cells 
over 72 hours. Compared to the control cells, the percentage 
of MCF10A cells in G
2
/M phase was increased from 9.6% 
at basal level to 14.8%, 17.5%, 21.4%, 21.7%, 73.8%, and 
78.4% after 4-, 8-, 12-, 24-, 48-, and 72-hour treatment with 
0.5 µM Danu, respectively (P0.01 or 0.001 by one-way 
ANOVA; Figure 3A and B). There was a marked increase 
in the percentage of MCF10A cells in G
2
/M phase when 
treated with Danu for 12 to 72 hours (P0.01 or 0.001 
by one-way ANOVA; Figure 3A and B). The percentage 
of MCF7 cells in G
2
/M phase was increased from 11.1% 
at basal level to 15.2%, 22.5%, 33.4%, and 55.6% after 
4, 8, 12, and 24 hours of treatment with 0.5 µM Danu, 
and declined to 39.9% and 22.7% after 48 and 72-hour 
treatment of Danu, respectively (P0.01 or 0.001 by 
one-way ANOVA; Figure 3A and B). There was a remark-
able increase in the percentage of MCF7 cells in G
2
/M 
phase after they were treated with Danu for 8 to 72 hours 
(P0.01 or 0.001 by one-way ANOVA; Figure 3A and 
B). The percentage of MDA-MB-231 cells in G
2
/M phase 
was increased from 11.4% at basal level to 23.3%, 26.5%, 
31.9%, and 70.4% after 4-, 8-, 12-, and 24-hour treatment 
with 0.5 µM Danu, and declined to 38.3% and 24.3% after 
48- and 72-hour treatment of 0.5 µM Danu, respectively 
(P0.01 or 0.001 by one-way ANOVA; Figure 3A and B). 
In addition, there was a marked increase in the percent-
age of MCF7 cells in G
2
/M phase when cells were treated 
with Danu for 4 to 72 hours (P0.01 or 0.001 by one-way 
ANOVA; Figure 3A and B). These data demonstrate a 
concentration- and time-dependent G
2
/M arrest in breast 
cancer cells by Danu.
Danu regulates the expression of cDK1/
cDc2, cDK2, cyclin B1, p21 Waf1/cip1, 
p27 Kip1, and p53 in McF10a, McF7, 
and MDa-MB-231cells
To explore the mechanism for Danu-induced cell cycle arrest, 
we examined the effect of Danu treatment on the expression 
levels of CDK1/CDC2, CDK2, cyclin B1, p21 Waf1/Cip1, p27 
Kip1, and p53 in MCF10A, MCF7, and MDA-MB-231 cells 
using Western blotting assay. The expression levels of CDK1/
CDC2, CDK2, and cyclin B1 were significantly decreased, 
whereas the expression levels of p21 Waf1/Cip1, p27 Kip1, 
and p53 were significantly increased in MCF10A, MCF7, 
and MDA-MB-231cells treated with Danu (Figure 4A and 
B). The expression of cyclin B1 was significantly suppressed 
in MCF10A cells with the treatment of Danu at 0.01, 0.1, and 
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0.5 µM for 24 hours. In comparison to the control cells, the 
expression level of cyclin B1 was decreased by 21%, 27%, 
and 65% when treated with 0.01, 0.1, and 0.5 µM Danu for 
24 hours, respectively. There was a 37.5%, 40.6%, and 67.2% 
reduction in the expression level of CDK1/CDC2 in MCF10A 
cells incubated with 0.01, 0.1, and 0.5 µM Danu for 24 hours, 
respectively. Treatment of MCF10A cells with Danu at 0.01, 
0.1, and 0.5 µM for 24 hours significantly increased the level 
of p27 Kip1 and p53 by 3.0-, 3.0-, and 7.5-fold and 5.1-, 6.6-, 
and 5.4-fold, respectively. However, there was no significant 
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Figure 3 Danu induces cell cycle arrest in McF10a, McF7, and MDa-MB-231cells in a time-dependent manner.
Notes: cells were treated with Danu at 0.5 µM for 4, 8, 12, 24, 48, and 72 hours and then subjected to flow cytometry. (A) Representative DNA fluorescence histograms 
of Pi-stained McF10a, McF7, and MDa-MB-231 cells, treated with Danu at 0.5 µM for 4 to 72 hours and (B) the bar graphs showing the percentage of McF10a, McF7, and 
MDa-MB-231 cells in g1 and g2/M phases. Data are expressed as the mean ± sD of three independent experiments. **P0.01; and ***P0.001 by one-way anOVa.
Abbreviations: Danu, danusertib; conc, concentration; sD, standard deviation; anOVa, analysis of variance; Pi, propidium iodide; hr, hour; Dip, diploid.
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Figure 4 Danu concentration-dependently modulates the expression levels of cDK1/cDc2, cDK2, cyclin B1, p21 Waf1/cip1, p27 Kip1, and p53 in McF10a, McF7, and 
MDa-MB-231cells. 
Notes: cells were treated with Danu at 0.01, 0.1, and 0.5 µM for 24 hours, and then the protein samples were subjected to Western blotting assay. (A) representative blots 
of cDK1/cDc2, cDK2, cyclin B1, p21 Waf1/cip1, p27 Kip1, and p53, and (B) bar graphs showing the relative expression levels of cDK1/cDc2, cDK2, cyclin B1, p21 Waf1/
cip1, p27 Kip1, and p53 in McF10a, McF7, and MDa-MB-231 cells. β-actin was used as the internal control. Data are expressed as the mean ± sD of three independent 
experiments. *P0.05; **P0.01; and ***P0.001 by one-way anOVa.
Abbreviations: cDK1/cDc2, cyclin dependent kinase 1/cell division cycle protein 2; cDK2, cyclin dependent kinase 2; Danu, danusertib; conc, concentration; sD, standard 
deviation; anOVa, analysis of variance.
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change in the expression levels of CDK2 and p21 Waf1/Cip1, 
when MCF10A cells were treated with 0.01, 0.1, and 0.5 µM 
Danu for 24 hours (P0.05, by one-way ANOVA; Figure 4A 
and B). The expression level of cyclin B1 was significantly 
decreased in MCF7 cells with the treatment of Danu at 0.1 
and 0.5 µM for 24 hours. In comparison to the control cells, 
the expression level of cyclin B1 was decreased 30.6% and 
29.2% when treated with 0.1 and 0.5 µM Danu for 24 hours, 
respectively. There was a 9.6%, 22.5%, and 38.5% reduction in 
the expression level of CDK1/CDC2 in MCF7 cells incubated 
with 0.01, 0.1, and 0.5 µM Danu for 24 hours, respectively. 
The expression level of CDK2 was decreased by 16.3% and 
35.9% when treated with 0.1 and 0.5 µM Danu for 24 hours, 
respectively. Treatment of MCF7 cells with Danu at 0.1 and 0.5 
µM for 24 hours significantly increased the level of p21 Waf1/
Cip1 and p27 Kip1 by 1.7- and 3.2-fold, and 1.9- and 2.5-fold, 
respectively. The expression level of p53 was increased 1.3-, 
1.4-, and 1.8-fold when treated with 0.01, 0.1, and 0.5 µM 
Danu for 24 hours in MCF7 cells, respectively (P0.01 or 
P0.001 by one-way ANOVA; Figure 4A and B). Similarly, 
treatment of MDA-MB-231 cells with Danu at 0.01, 0.1, and 
0.5 µM for 24 hours significantly decreased by 24.4%, 39.8%, 
and 46.3% in the level of CDK1/CDC2 and 17.9%, 16.1%, 
and 30.4% in the level of CDK2, respectively. There was a 
12.8%, 55.3%, and 53.2% reduction in the expression level 
of cyclin B1 in MDA-MB-231 cells incubated with 0.01, 0.1, 
and 0.5 µM Danu for 24 hours, respectively. Treatment of 
MDA-MB-231 cells with Danu at 0.01, 0.1, and 0.5 µM for 24 
hours significantly increased the level of p21 Waf1/Cip1 and 
p27 Kip1 by 1.4-, 2.4-, and 3.6-fold, and 3.5-, 3.6-, and 10.1-
fold, respectively. The expression level of p53 was increased 
1.4-, 1.5-, and 2.4-fold when treated with 0.01, 0.1, and 0.5 
µM Danu for 24 hours in MDA-MB-231 cells, respectively 
(P0.01 or 0.001 by one-way ANOVA; Figure 4A and B).
To further investigate the molecular mechanism for 
Danu-induced cell cycle arrest, we conducted separate 
experiments to evaluate the expression levels of CDK1/
CDC2, cyclin B1, p21 Waf1/Cip1, and p53 in MCF10A, 
MCF7, and MDA-MB-231 cells with the treatment of Danu 
over 72 hours using Western blotting assay. Treatment of 
MCF10A cells with Danu at 0.5 µM for 4, 8, 12, 24, 48, 
and 72 hours significantly decreased the level of cyclin 
B1 by 16.2%, 26.6%, 48.7%, 90.9%, 91.1%, and 96.2%, 
respectively. There was a 23.1%, 8.3%, 16.9%, 15.3%, 
and 15.4% reduction in the expression level of CDK1/
CDC2 in MCF10A cells incubated with 0.5 µM Danu 
for 4, 8, 12, 24, and 72 hours, respectively. Treatment of 
MCF10A cells with Danu at 0.5 µM for 8, 24, and 48 hours 
significantly increased the level of p21 Waf1/Cip1 by 1.6-, 
4.1-, and 1.9-fold, respectively. The expression level of 
p53 was increased 2.2-, 2.4-, 5.9-, 3.9-, and 4.1-fold when 
treated with 0.5 µM Danu for 8, 12, 24, 48, and 72 hours 
in MCF10A cells, respectively (P0.01 or 0.001 by one-
way ANOVA;  Figure 5A and B). Incubation of MCF7 
cells with Danu at 0.5 µM for 4, 8, 24, 48, and 72 hours 
significantly decreased the level of CDK1/CDC2 by 28.4%, 
19.0%, 19.1%, 46.9%, and 64.0%, respectively. There was 
a 29.7%, 38.0%, and 38.2% reduction in the expression 
level of cyclin B1 in MCF7 cells incubated with 0.5 µM 
Danu for 8, 24, and 72 hours, respectively. Treatment of 
MCF7 cells with Danu at 0.5 µM for 8, 24, and 72 hours 
significantly increased the level of p21 Waf1/Cip1 by 
3.2-, 4.4-, and 10-fold, respectively. The expression level 
of p53 was increased 1.7-, 1.7-, and 2.3-fold when treated 
with 0.5 µM Danu for 12, 24, and 72 hours in MCF7 cells, 
respectively (P0.01 or 0.001 by one-way ANOVA; Fig-
ure 5A and B).
Treatment of MDA-MB-231 cells with Danu at 0.5 µM 
for 4, 8, 12, 24, 48, and 72 hours significantly decreased 
the level of CDK1/CDC2 by 26.6%, 37.5%, 48.8%, 50.8%, 
28.6%, and 42.8%, respectively. There was a 26% reduction 
in the expression level of cyclin B1 in MDA-MB-231 cells 
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Figure 5 Danu time-dependently regulates the expression levels of cDK1/cDc2, cDK2, cyclin B1, p21 Waf1/cip1 and p53 in McF10a, McF7, and MDa-MB-231cells. 
Notes: cells were treated with 0.5 µM Danu for 4, 8, 12, 24, 48, and 72 hours, and then the protein samples were subjected to Western blotting assay. (A) representative 
blots of cDK1/cDc2, cDK2, cyclin B1, p21 Waf1/cip1, and p53, and (B) bar graphs showing the relative levels of cDK1/cDc2, cDK2, cyclin B1, p21 Waf1/cip1, and 
p53 in McF10a, McF7, and MDa-MB-231 cells. β-actin was used as the internal control. Data are expressed as the mean ± sD of three independent experiments. *P0.05; 
**P0.01; and ***P0.001 by one-way anOVa.
Abbreviations: Danu, danusertib; conc, concentration; sD, standard deviation; anOVa, analysis of variance; hr, hour.
incubated with 0.5 µM Danu for 72 hours. Treatment of 
MDA-MB-231 cells with Danu at 0.5 µM for 8, 24, and 
48 hours significantly increased the expression level of p21 
Waf1/Cip1 by 2.6-, 1.6-, and 1.2-fold, respectively. The 
expression level of p53 was increased 1.6- and 1.7-fold 
when treated with 0.5 µM Danu for 8 and 72 hours in MDA-
MB-231 cells, respectively (P0.01 or 0.001 by one-way 
ANOVA; Figure 5A and B).
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Danu induces the apoptosis of McF10a, 
McF7, and MDa-MB-231 cells via 
activation of mitochondrial pathway
To examine the apoptosis-inducing effect of Danu in 
MCF10A, MCF7, and MDA-MB-231 cells, the number of 
apoptotic cells was first quantified using a flow cytometric 
analysis; the results are shown in Figure 6A and B. The 
number of apoptotic cells was 12.7%, 16.7%, and 15.8% 
in MCF10A, MCF7, and MDA-MB-231 cells treated with 
the control vehicle only (0.05% DMSO, v/v), respectively. 
In MCF10A cells treated with Danu at 0.1 and 0.5 µM for 
24 hours, the total percentages of apoptotic cells (early 
plus late apoptosis) were 20.1% and 36.6%, respectively, 
with a 1.6- and 2.9-fold increase compared to the control 
cells. When MCF7 cells were treated with Danu at 0.01, 
0.1, and 0.5 µM for 24 hours, the total percentages of 
apoptotic cells were increased 1.4-, 2.0-, and 2.6-fold 
compared to the control cells, respectively. Similarly, 
MDA-MB-231 cells were treated with Danu at 0.1 and 
0.5 µM for 24 hours, the total percentages of apoptotic 
cells were increased 2.2- and 3.0-fold compared to the 
control cells, respectively (P0.05 by one-way ANOVA; 
Figure 6A and B).
To investigate the mechanism responsible for Danu-
induced apoptosis in MCF10A, MCF7, and MDA-MB-231 
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Figure 6 Danu induces apoptotic death in McF10a, McF7, and MDa-MB-231 cells. 
Notes: (A) Flow cytometric dot plots of specific cell populations (live, early apoptosis, and late apoptosis) in MCF10A, MCF7, and MDA-MB-231 cells treated with Danu at 
0.01, 0.1, and 0.5 µM for 24 hours, and (B) bar graphs showing the percentage of apoptotic cells in McF10a, McF7, and MDa-MB-231 cells treated with Danu at 0.01, 0.1, 
and 0.5 µM for 24 hours. an annexin-V:Pe/7-aaD double staining assay was conducted to detect the apoptosis of the cells. The cells were stained with 7-aaD to distinguish 
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cells, we evaluated the levels of Bcl-xl, Bcl-2, Bax, PUMA, 
cleaved caspase 3, and cleaved caspase 9 in the above three 
cell lines treated with Danu at 0.01, 0.1, and 0.5 µM for 
24 hours. We first examined the effects of Danu treatment 
on the expression levels of the pro-apoptotic protein Bax and 
the anti-apoptotic proteins Bcl-2 and Bcl-xl. The expression 
level of Bax was concentration-dependently increased in three 
cell lines (P0.05 by one-way ANOVA; Figure 7A and B). 
Incubation of MCF10A cells with 0.01 and 0.5 µM Danu 
for 24 hours significantly increased Bax expression 2.0-fold; 
treatment of MCF7 cells with 0.01 and 0.5 µM Danu for 24 
hours resulted in an 1.2- and 1.4-fold increase in the expres-
sion of Bax, respectively; treatment of MDA-MB-231 cells 
with 0.01, 0.1, and 0.5 µM Danu for 24 hours remarkably 
increased the expression of Bax 2.0-fold. In contrast, the 
expression level of Bcl-2 was decreased by 46.4%, 58.0%, 
and 47.6% in MCF10A cells, 50.0%, 60.0%, and 55.0% in 
MCF7 cells, and 26.0%, 39.0%, and 50.0% in MDA-MB-
231 cells when treated with Danu at 0.01, 0.1, and 0.5 µM, 
respectively. In addition, the expression level of Bcl-xl was 
significantly suppressed after treatment with Danu at 0.01, 
0.1, and 0.5 µM in MCF7 and MDA-MB-231 cells cell lines. 
Compared to the control cells, the expression level of Bcl-xl 
was reduced by 21.4%, 42.9%, and 65.7% in MCF7 cells and 
30.7%, 42%, and 37.2% in MDA-MB-231 cells when treated 
with Danu at 0.01, 0.1, and 0.5 µM for 24 hours, respectively 
(P0.01 by one-way ANOVA; Figure 7A and B). However, 
there was no significant alteration in the expression level of 
Bcl-xl, when MCF10A cells were incubated with 0.01, 0.1, 
and 0.5 µM Danu for 24 hours (P0.05 by one-way ANOVA; 
Figure 7A and B). 
Additionally, the effect of Danu on the expression of 
PUMA was examined due to its important role in the regulation 
of anti-apoptotic proteins. Incubation of MCF10A, MCF7, and 
MDA-MB-231 cells with Danu increased the  expression level 
of PUMA in a concentration-dependent manner. Treatment of 
cells with 0.01, 0.1, and 0.5 µM Danu for 24 hours significantly 
increased 1.4-fold in the  expression level of PUMA in MCF7 
and MDA-MB-231 cells (P0.01 by one-way ANOVA; Fig-
ure 7A and B). In MCF10A cells, the expression level of PUMA 
increased 3.0- and 7.4-fold when treated with Danu at 0.1 and 
0.5 µM for 24 hours (P0.05 by one-way ANOVA; Figure 7A 
and B). Subsequently, we observed a significant increase in 
the activation of caspases 9 and 3 in MCF10A, MCF7, and 
MDA-MB-231 cells. Incubation of MCF10A with Danu at 0.1 
and 0.5 µM for 24 hours significantly increased the level of 
cleaved caspase 3 and cleaved caspase 9 by 2.3- and 3.2-fold, 
respectively (P0.05 by one-way ANOVA; Figure 7A and B). 
Similarly, treatment of MCF7 and MDA-MB-231 cells with 
0.01, 0.1, and 0.5 µM Danu for 24 hours significantly increased 
the expression level of cleaved caspase 9 by 1.6-, 2.4-, and 
3.2-fold, respectively, in both cell lines (P0.001 by one-way 
ANOVA; Figure 7A and B). The level of cleaved caspase 3 was 
also increased 1.5- and 1.6-fold when MCF7 and MDA-MB-
231 cells were treated with 0.1 and 0.5 µM Danu for 24 hours, 
respectively (P0.01 by one-way ANOVA; Figure 7A and B). 
These results indicate that Danu induces a remarkable activa-
tion of caspases 9 and 3, and eventually leads to apoptotic death 
of MCF10A, MCF7, and MDA-MB-231 cells.
Danu induces the autophagy of McF10a, 
McF7, and MDa-MB-231 cells
Autophagy is a type II programmed cell death and a cyto-
protective mechanism against extracellular stress. To deter-
mine the effect of Danu on autophagy, we first determined 
autophagic MCF10A, MCF7, and MDA-MB-231 cells using 
flow cytometric analysis. Danu treatment of MCF10A, MCF7, 
and MDA-MB-231 cells induced remarkable autophagy 
 (Figures 8 and 9). In MCF10A cells, the percentage of 
autophagic cells at basal level was 0.56%; and incubation 
MCF10A cells
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Figure 7 Danu modulates the expression of key pro- and anti-apoptotic molecules in McF10a, McF7, and MDa-MB-231 cells.
Notes: cells were treated with Danu at 0.01, 0.1, and 0.5 µM for 24 hours, and then the protein samples were subjected to Western blotting assay. (A) representative blots 
of Bcl-xl, Bcl-2, Bax, PUMa, cleaved caspase 3, and cleaved caspase 9 in McF10a, McF7, and MDa-MB-231 cells, and (B) bar graphs showing the relative levels of Bcl-xl, 
Bcl-2, Bax, PUMa, cleaved caspase 3, and cleaved caspase 9 in McF10a, McF7, and MDa-MB-231 cells. β-actin was used as the internal control. Data are expressed as the 
mean ± sD of three independent experiments. *P0.05; **P0.01; and ***P0.001 by one-way anOVa.
Abbreviations: Danu, danusertib; conc, concentration; sD, standard deviation; anOVa, analysis of variance; casp, caspase; PUMa, p53-upregulated modulator of apoptosis; 
Bax, Bcl-2-associated X protein; Bcl-2, B-cell lymphoma 2; Bcl-xl, B-cell lymphoma-extra-large.
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Figure 8 Danu concentration-dependently induces autophagic cell death in McF10a, McF7, and MDa-MB-231 cells. 
Notes: cells were treated with Danu at 0.01, 0.1, and 0.5 µM for 24 hours, and then subjected to flow cytometric analysis with Cyto-ID® as the green stain for autophagic 
vacuoles. (A) Flow cytometric dot plots of the percentage of autophagic McF10a, McF7, and MDa-MB-231 cells, and (B) bar graphs showing the percentage of autophagic 
McF10a, McF7, and MDa-MB-231 cells. Data are expressed as the mean ± sD of three independent experiments. **P0.01 and ***P0.001 by one-way anOVa.
Abbreviations: Danu, danusertib; conc, concentration; sD, standard deviation; anOVa, analysis of variance.
of the cells with Danu at 0.5 µM significantly increased the 
autophagy 10.9-fold (P0.001 by one-way ANOVA; Figure 
8A and B). Treatment of MCF10A cells with 0.5 µM Danu for 
24, 48, and 72 hours increased the autophagy 5.0-, 5.2-, and 
9.5-fold, respectively (P0.05 by one-way ANOVA; Figure 
9A and B). In MCF7 cells, the percentage of autophagic cells 
at basal level was 3.6%; incubation of the cells with Danu at 
0.1 and 0.5 µM significantly increased the autophagy 6.4- and 
6.0-fold, respectively (P0.01 by one-way ANOVA; Figure 
8A and B). Incubation of MCF7 cells with 0.5 µM Danu for 
24, 48, and 72 hours increased the autophagy 9.2-, 23.6-, 
and 50.6-fold, respectively (P0.01 by one-way ANOVA; 
Figure 9A and B). Similarly, in MDA-MB-231 cells, the 
 percentage of autophagic cells at basal level was 1.3%; 
incubation of the cells with Danu at 0.5 µM significantly 
increased the autophagy 17.5-fold (P0.001 by one-way 
ANOVA; Figure 8A and B). Exposure of MDA-MB-231 
cells to 0.5 µM Danu for 24, 48, and 72 hours increased the 
autophagy 6.2-, 14.1-, and 11.9-fold, respectively (P0.01 
by one-way ANOVA; Figure 9A and B).
Next, we examined the effect of Danu on the expression 
levels of beclin 1, LC3-I, and LC3-II. Beclin 1 plays an pivotal 
role in the process of autophagy through the formation of a 
complex with vacuolar protein sorting 34 (Vps34, also called 
class III PI3K) and recruitment of other Atgs that are critical 
for subsequent autophagosome formation.22 Upon autophagy 
initiation, LC3 is cleaved at the C-terminus by Atg4 to form the 
cytosolic LC3-I.23 LC3-I is consequently proteolytically cleaved 
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Figure 9 Danu induces autophagic cell death in McF10a, McF7, and MDa-MB-231 cells in a time-dependent manner.
Notes: cells were treated with Danu at 0.5 µM for 4, 8, 12, 24, 48, and 72 hours, and then subjected to flow cytometry with Cyto-ID® as the green stain for autophagic 
vacuoles. (A) Flow cytometric dot plots showing autophagic McF10a, McF7, and MDa-MB-231 cells, and (B) bar graphs showing the percentage of autophagic McF10a, 
McF7, and MDa-MB-231 cells. Data are expressed as the mean ± sD of three independent experiments. *P0.05; **P0.01; and ***P0.001 by one-way anOVa.
Abbreviations: Danu, danusertib; conc, concentration; sD, standard deviation; anOVa, analysis of variance; hr, hour.
and  lipidated by Atg3 and Atg7 to form LC3-II, which localizes 
to the autophagosome membrane. Treatment of MCF7 cells 
with Danu at 0.01, 0.1, and 0.5 µM for 24 hours significantly 
increased the expression level of beclin 1 1.5-, 1.4-, and 1.5-fold, 
respectively, compared to the control cells (P0.001 by one-
way ANOVA; Figure 10A and B). There was a 1.2- and 1.4-fold 
increase in the level of beclin 1 in MDA-MB-231 cells treated 
with 0.1 and 0.5 µM Danu for 24 hours, respectively (P0.01 by 
one-way ANOVA; Figure 10A and B). However, incubation of 
MCF10A cells with Danu at 0.01, 0.1, and 0.5 µM for 24 hours 
did not significantly alter the expression level of beclin 1 
(P0.05 by one-way ANOVA; Figure 10A and B). After 
24-hour treatment with Danu at 0.01, 0.1, and 0.5 µM, our 
Western blotting analysis revealed two clear bands of LC3-I 
and -II in both MCF7 and MDA-MB-231 cells. In both MCF7 
and MDA-MB-231 cells, there was a concentration-dependent 
increase in the expression of LC3-II (P0.001 by one-way 
ANOVA; Figure 10A and B). Compared to the control cells, 
there was a 1.6-fold increase in the LC3-II level in MCF7 cells 
treated with Danu at 0.5 µM for 24 hours (P0.001 by one-way 
ANOVA; Figure 10A and B). In MDA-MB-231 cells, treat-
ment with 0.1 and 0.5 µM Danu resulted in a 2.0- and 3.2-fold 
increase in the expression of LC3-II, respectively, compared 
to the control cells (P0.01 by one-way ANOVA; Figure 10A 
and B). In addition, treatment of MCF7 and MDA-MB-231 
cells with Danu decreased the expression of LC3-I, although 
expression was not significantly different. In MCF10A cells, the 
relative expression level of LC3-II was negligible (0.02–0.03) 
in the control cells treated with the control vehicle only (0.05% 
DMSO, v/v) and treated with Danu at 0.01 and 0.1 µM (Fig-
ure 10A and B).
To further elucidate the effect of Danu on autophagy in 
three breast cell lines, we examined the effect of Danu on 
the expression levels of beclin 1 and LC3-II over 72 hours. 
Treatment of MCF7 cells with Danu at 0.5 µM for 8, 12, 24, 
and 72 hours significantly increased the expression of beclin 
1 by 1.5-, 1.6-, 1.5-, and 2.5-fold, respectively, compared to 
the control cells (P0.01 by one-way ANOVA; Figures 11B 
and 12B). There was a 1.2-, 1.4-, and 1.6-fold increase of 
beclin 1 in MDA-MB-231 cells treated with 0.5 µM Danu 
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for 12, 24, and 48 hours, respectively (P0.001 by one-way 
ANOVA; Figures 11C and 12C). However, incubation of 
MCF10A cells with Danu at 0.5 µM over 72 hours did not 
significantly alter the expression level of beclin 1 (P0.05 
by one-way ANOVA; Figures 11A and 12A). In both MCF7 
and MDA-MB-231 cells, there was a marked increase in 
the expression of LC3-II. Compared to the control cells, 
there was a 2.1-, 2.1, and 2.6-fold increase in the LC3-II 
level in MCF7 cells treated with Danu at 0.5 µM for 4, 12, 
and 48 hours, respectively (P0.01 by one-way ANOVA; 
Figures 11B and 12B). In MDA-MB-231 cells, 0.5 µM 
Danu over 72 hours resulted in a 1.5- and 2.5-fold increase 
in the expression of LC3-II, compared to the control cells 
(P0.001 by one-way ANOVA; Figures 11C and 12C). In 
MCF10A cells, the relative expression level of LC3-II was 
also negligible (0.02–0.05) when cells were treated with 
Danu at 0.5 µM for 4, 8, 12, and 24 hours (Figures 11A and 
12A). These results indicate that Danu induces autophagy in 
breast cancer cells, and MCF10A cells are less sensitive to 
Danu-induced autophagy than malignant MCF7 and MDA-
MB-231 cells.
Danu induces the activation of p38 
MaPK and erk1/2
MAPK family members, including c-Jun N-terminal kinase 
(JNK), Erk1/2, and p38 MAPK, have been reported to be 
involved in autophagy. To investigate whether the p38 MAPK 
and Erk1/2 signaling pathways were involved in Danu-
induced autophagy, Western blotting assay was performed 
to detect the activated state of associated proteins. As shown 
in Figures 10, 11, and 12, Danu remarkably inhibited the 
phosphorylation of p38 MAPK; on the contrary, Danu induced 
the phosphorylation of Erk1/2 in three breast cell lines. 
First, we examined the effect of Danu on the phospho-
rylation of p38 MAPK at Thr180/Tyr182 in the three cell 
lines. Exposure of MCF10A, MCF7, and MDA-MB-231 
cells to 0.01, 0.1, and 0.5 µM Danu for 24 hours increased 
the phosphorylation level of p38 MAPK at Thr180/Tyr182; 
however, incubation of three cell lines with Danu did not 
significantly affect the expression of total p38 MAPK. The 
ratio of p-p38 MAPK at Thr180/Tyr182 over total p38 MAPK 
was concentration-dependently increased by Danu in both cell 
lines compared to the control cells. In MCF7 cells, the p-p38 
MAPK/p38 MAPK ratio was increased from 0.29 at basal 
level to 0.32 and 0.64, when MCF7 cells were treated with 
Danu at 0.1 and 0.5 µM, respectively (P0.001 by one-way 
ANOVA; Figure 10A and B). In MDA-MB-231 cells, 0.01, 
0.1, and 0.5 µM Danu significantly decreased the ratio of 
p-p38 MAPK over p38 MAPK from 0.29 at basal level to 0.46, 
0.58, and 0.75, respectively (P0.001 by one-way ANOVA; 
Figure 10A and B). In MCF10A cells, only 0.5 µM Danu 
increased the ratio of p-p38 MAPK over total p38 MAPK. 
Treatment of MCF10A, MCF7, and MDA-MB-231 cells with 
Danu at 0.01, 0.1, and 0.5 µM for 24 hours increased the phos-
phorylation level of Erk1/2 at Thr202/Tyr204, but incubation 
of these three cell lines with Danu did not significantly affect 
the expression of total Erk1/2. The ratio of p-Erk1/2 over total 
Erk1/2 was concentration-dependently increased by Danu in 
all three cell lines compared to the control cells. In MCF7 cells, 
the p-Erk1/2:Erk1/2 ratio was increased from 0.45 at basal 
level to 0.65, 0.55, and 0.53, when MCF7 cells were treated 
with Danu at 0.01, 0.1, and 0.5 µM, respectively (P0.001 
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Figure 10 Danu modulates the phosphorylation of p38 MaPK, erk1/2, akt, mTOr and the expression of beclin 1, lc3-i, and lc3-ii in McF10a, McF7, and MDa-MB-231 
cells. 
Notes: McF10a, McF7, and MDa-MB-231 cells were treated with Danu at 0.01, 0.1, and 0.5 µM for 24 hours, and the protein samples were subjected to Western blotting 
assay. (A) representative bolts of p-p38 MaPK, p38 MaPK, p-erk1/2, erk1/2, p-akt, akt, p-mTOr, mTOr, beclin 1, lc3-i, and lc3-ii, and (B) bar graphs showing the ratio 
of p-p38 MaPK/p38 MaPK, p-erk1/2/erk1/2, p-akt/akt, and p-mTOr/mTOr, and the relative levels of beclin 1 and lc3-ii. β-actin was used as the internal control. Data are 
expressed as the mean ± sD of three independent experiments. *P0.05; **P0.01; and ***P0.001 by one-way anOVa.
Abbreviations: Danu, danusertib; conc, concentration; sD, standard deviation; anOVa, analysis of variance; p, phosphorylated; MaPK, mitogen-activated protein kinase; 
erk1/2, extracellular signal-regulated kinases 1 and 2; akt, protein kinase B; mTOr, mammalian target of rapamycin; lc3, microtubule-associated protein 1a/1B-light chain 3.
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by one-way ANOVA; Figure 10A and B). In MDA-MB-231 
cells, 0.1 and 0.5 µM Danu significantly increased the ratio of 
p-Erk1/2 over total Erk1/2 from 0.83 at basal level to 1.08 and 
1.23, respectively (P0.001 by one-way ANOVA; Figure 10A 
and B). In MCF10A cells, only 0.5 µM Danu increased the 
ratio of p-Erk1/2 over total Erk1/2 from 0.42 at basal level to 
0.71 (P0.05 by one-way ANOVA; Figure 10A and B). 
We further investigated the activation of MAPK by Danu 
in breast epithelial cell lines over 72 hours. A time-course 
study of p38 MAPK and Erk1/2 phosphorylation in MCF-7 
and MDA-MB-231 cells showed that the activation of p38 
MAPK and Erk1/2 was increased with drug treatment time. In 
MCF7 cells, the p-p38 MAPK/p38 MAPK ratio was increased 
from 0.26 at basal level to 0.30, 0.42, 0.46, 0.27, 0.4, and 
0.76, when MCF7 cells were treated with Danu at 0.5 µM 
for 4, 8, 12, 24, 48, and 72 hours, respectively (P0.001 by 
one-way ANOVA; Figures 11B and 12B). In MDA-MB-231 
cells, treatment with 0.5 µM Danu for 24, 48, and 72 hours 
significantly increased the ratio of p-p38 MAPK over total 
p38 MAPK from 0.06 at basal level to 0.09, 0.14, and 0.09, 
respectively (P0.001 by one-way ANOVA; Figures 11C and 
12C). In MCF10A cells, treatment with 0.5 µM Danu for 48 
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Figure 11 effects of Danu treatment over 72 hours on phosphorylation levels of p38 MaPK, erk1/2, akt, and mTOr, and the levels of beclin 1, lc3-i, and lc3-ii in McF10a, 
McF7, and MDa-MB-231 cells. 
Notes: cells were treated with Danu for 4, 8, 12, 24, 48, and 72 hours, and β-actin was used as the internal control. (A) representative blots of p-p38 MaPK, p38 MaPK, 
p-erk1/2, erk1/2, p-akt, akt, p-mTOr, mTOr, beclin 1, lc3-i, and lc3-ii in McF10a cells, (B) McF7 cells, and (C) MDa-MB-231 cells. 
Abbreviations: Danu, danusertib; conc, concentration; p, phosphorylated; MaPK, mitogen-activated protein kinase; erk1/2, extracellular signal-regulated kinases 1 and 2; 
akt, protein kinase B; mTOr, mammalian target of rapamycin; lc3, microtubule-associated protein 1a/1B-light chain 3
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Figure 12 Bar graphs showing the ratio of p-p38 MaPK/p38 MaPK, p-erk1/2/erk1/2, p-akt/akt, and p-mTOr/mTOr, and the relative levels of beclin 1 and lc3-ii in 
(A) McF10a cells, (B) McF7 cells, and (C) MDa-MB-231 cells.
Notes: cells were treated with Danu for 4, 8, 12, 24, 48, and 72 hours, and β-actin was used as the internal control. Data are expressed as the mean ± sD of three 
independent experiments. *P0.05; **P0.01; and ***P0.001 by one-way anOVa.
Abbreviations: Danu, danusertib; conc, concentration; sD, standard deviation; anOVa, analysis of variance; p, phosphorylated; MaPK, mitogen-activated protein kinase; 
erk1/2, extracellular signal-regulated kinases 1 and 2; akt, protein kinase B; mTOr, mammalian target of rapamycin; lc3, microtubule-associated protein 1a/1B-light 
chain 3; hr, hour.
and 72 hours increased the ratio of p-p38 MAPK over total 
p38 MAPK from 0.05 at basal level to 0.07 (P0.05 by one-
way ANOVA; Figures 11A and 12A). Treatment of MCF10A, 
MCF7, and MDA-MB-231 cells with Danu at 0.5 µM over 
72 hours increased the activation of Erk1/2 at Thr202/Tyr204. 
In MCF7 cells, the p-Erk1/2:Erk1/2 ratio was increased from 
0.41 at basal level to 0.65 and 0.72, when MCF7 cells were 
treated with 0.5 µM Danu for 12 and 24 hours, respectively 
(P0.05 by one-way ANOVA; Figures 11B and 12B). 
In MDA-MB-231 cells, treatment with 0.5 µM Danu sig-
nificantly increased the ratio of p-Erk1/2 over total Erk1/2 
from 0.09 at basal level to 0.14, 0.22, and 0.22, respectively 
(P0.001 by one-way ANOVA; Figures 11C and 12C). In 
MCF10A cells, only 0.5 µM Danu for 72 hours increased the 
ratio of p-Erk1/2 over total Erk1/2 from 1.69 at basal level to 
2.09 (P0.05 by one-way ANOVA; Figures 11A and 12A). 
These observations indicate the involvement of p38 MAPK 
and Erk1/2 in Danu-induced autophagy.
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effects of p38 MaPK and erk1/2 
activation on Danu-induced autophagy
Recent studies have demonstrated the involvement of p38 
MAPK and Erk1/2 signaling pathways in autophagy. In our 
study, treatment with Danu for more than 24 hours resulted 
in the sustained activation of p38 MAPK and Erk1/2, and 
significantly increased expression of LC3-II and beclin 1. 
Thus, to further investigate the roles of p38 MAPK and Erk1/2 
in Danu-induced autophagy, we used the autophagy inhibitor 
WM, an inhibitor for the sequestration step of autophago-
somes, and bafilomycin A1, an inhibitor for the maturation 
step of autophagosomes. First, we examined the effects of 
autophagy inhibitors on Danu-induced autophagy in MCF7 
and MDA-MB-231 cells using flow cytometry. In MCF7 
cells, WM at 10 µM decreased Danu-induced autophagy 
by 31.3%; however, bafilomycin A1 at 100 nM increased 
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Figure 13 The effects of autophagy inhibitors alone or in combination with Danu on the autophagy of McF7 and MDa-MB-231 cells. 
Notes: cells were pretreated with WM (10 µM) or bafilomycin A1 (100 nM) for 30 minutes, 0.5 µM Danu was added for further incubation for 24 hours, and then cells 
were harvested. The percentage of autophagic MCF7 and MDA-MB-231 cells was examined by flow cytometry with Cyto-ID® as the green stain for autophagic vacuoles. (A) 
Flow cytometric dot plots showing the autophagic McF7 and MDa-MB-231 cells, and (B) bar graphs showing the percentage of autophagic cells treated with Danu at 0.5 µM 
for 24 hours inhibited by inhibitors of autophagy alone or in combination with Danu. Data are expressed as the mean ± sD of three independent experiments. *P0.05; 
**P0.01; and ***P0.001 by one-way anOVa.
Abbreviations: Danu, danusertib; SD, standard deviation; ANOVA, analysis of variance; p, phosphorylated; WM, wortmannin; DMSO, dimethyl sulfoxide; Baf A1, bafilomycin A1.
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Danu-induced autophagy 1.2-fold, compared to the control 
cells treated with Danu alone (P0.05 by one-way ANOVA; 
Figure 13A and B). In MDA-MB-231 cells, WM at 10 µM 
also decreased Danu-induced autophagy by 45.4%; however, 
bafilomycin A1 at 100 nM increased Danu-induced autophagy 
1.3-fold, compared to the control cells treated with Danu 
alone (P0.001 by one-way ANOVA; Figure 13A and B). 
Furthermore, we examined the expression levels of 
beclin 1 and LC3-II when MCF7 and MDA-MB-231 
cells were treated with Danu alone or in combination with 
autophagy inhibitors, by Western blotting assay. Treatment 
of cells with 0.5 µM Danu in combination with 10 µM WM 
or 100 nM bafilomycin A1 decreased the expression level 
of beclin 1 by 83.12% and 66.9% in MCF7 cells, respec-
tively, compared to the control cells treated with Danu alone 
(P0.001 by one-way ANOVA; Figure 14A and B). How-
ever, in MDA-MB-231 cells, incubation of cells with 0.5 µM 
Danu in combination with 10 µM WM or 100 nM bafilo-
mycin A1 did not significantly change the level of beclin 1 
(P0.05 by one-way ANOVA; Figure 14A and B). Treating 
cells with 0.5 µM Danu in combination with 10 µM WM 
decreased the level of LC3-II by 96.2% in MCF7 cells (P0.01 
by one-way ANOVA; Figure 14A and B). In MDA-MB-231 
cells, treatment of cells with 0.5 µM Danu in combination 
with 10 µM WM decreased the level of LC3-II by 25.0%, but 
there was no significant difference compared to the control 
cells treated with Danu alone (P0.05 by one-way ANOVA; 
Figure 14A and B). Danu (0.5 µM) combined with 100 nM 
bafilomycin A1 increased the expression level of LC3-II in 
MCF7 cells and MDA-MB-231 cells by 3.9- and 12.2-fold, 
respectively, compared to the control cells treated with Danu 
alone (P0.001 by one-way ANOVA; Figure 14A and B). 
In addition, we examined the activation of p38 MAPK at 
Thr180/Tyr182 and Erk1/2 at Thr202/Tyr204 when cells were 
treated with WM and bafilomycin A1 prior to Danu treatment. 
In MCF7 and MDA-MB-231 cells, pretreatment with WM prior 
to Danu markedly attenuated the phosphorylation of p38 MAPK 
and Erk1/2 compared to the control cells treated with Danu alone 
(P0.001 by one-way ANOVA; Figure 14A and B). Moreover, 
pretreatment with bafilomycin A1 prior to Danu decreased the 
ratio of p-p38 MAPK over total p38 MAPK, and p-Erk1/2 
over total Erk1/2 in MCF7 cells, compared to the control cells 
treated with Danu alone (P0.05 by one-way ANOVA; Figure 
15A and B). In MDA-MB-231 cells, there was no significant 
difference (P0.05 by one-way ANOVA; Figure 15A and 
B). Taken together, these results show that pretreatment with 
WM inhibits Danu-induced autophagy, but pretreatment with 
bafilomycin A1 markedly increases Danu-induced autophagy. 
These observations suggest that p38 MAPK and Erk1/2 regulate 
autophagosome formation at the sequestration step.
p38 MaPK regulates Danu-induced 
autophagy via akt activation
We further dissected the roles of p38 MAPK and Erk1/2 
in Danu-induced autophagy. Cells were pretreated with 
SB202190 (a p38 MAPK inhibitor) or U0126 (an Erk1/2 
inhibitor) for 30 minutes, and then treated with Danu for a 
further 24 hours. First, we examined the effects of SB202190 
and U0126 on Danu-induced autophagy in MCF7 and 
MDA-MB-231 cells using flow cytometry. In MCF7 cells 
and MDA-MB-231 cells, 10 µM SB202190 decreased Danu-
induced autophagy; however, there was no significant differ-
ence compared to the control cells treated with Danu alone 
(P0.05 by one-way ANOVA; Figure 16A and B). Ten µM 
U0126 significantly decreased Danu-induced autophagy by 
32.7% and 32.4% in MCF7 and MDA-MB-231 cells, respec-
tively, compared to the control cells treated with Danu alone 
(P0.01 by one-way ANOVA; Figure 16A and B). Next, we 
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Figure 14 effects of various chemical modulators on the expression levels of beclin 1 and lc3-ii in McF7 cells and MDa-MB-231 cells. 
Notes: cells were pretreated with WM (10 µM), bafilomycin A1 (100 nM), SB202190 (10 µM), or U0126 (10 µM) for 30 minutes, 0.5 µM Danu was added and incubated 
for a further 24 hours, cells were harvested, and protein samples were subjected to Western blotting assay. (A) representative blots of beclin 1 and lc3-ii in McF7 cells 
and MDa-MB-231 cells, and (B) bar graphs showing the relative levels of beclin 1 and lc3-ii. β-actin was used as the internal control. Data are expressed as the mean ± sD 
of three independent experiments. *P0.05; **P0.01; and ***P0.001 by one-way anOVa.
Abbreviations: Danu, danusertib; conc, concentration; sD, standard deviation; anOVa, analysis of variance; lc3, microtubule-associated protein 1a/1B-light chain 3; 
WM, wortmannin; DMSO, dimethyl sulfoxide; Baf A1, bafilomycin A1.
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Figure 15 effects of two autophagy inhibitors on the activation of p38 MaPK and erk1/2 in McF7 and MDa-MB-231 cells. 
Notes: McF7 and MDa-MB-231 cells were pretreated with WM (10 µM) or bafilomycin A1 (100 nM) for 30 minutes before adding 0.5 µM Danu for further incubation 
of 24 hours. cells were then harvested and protein samples were subjected to Western blotting assay. (A) representative blots of p-p38 MaPK, p38 MaPK, p-erk1/2, and 
erk1/2 in McF7 and MDa-MB-231 cells, and (B) bar graphs showing the ratio of p-p38 MaPK/p38 MaPK and p-erk1/2/erk1/2 in McF7 and MDa-MB-231 cells. β-actin was 
used as the internal control. Data are expressed as the mean ± sD of three independent experiments. *P0.05; **P0.01; and ***P0.001 by one-way anOVa.
Abbreviations: Danu, danusertib; sD, standard deviation; anOVa, analysis of variance; p, phosphorylated; MaPK, mitogen-activated protein kinase; erk1/2, extracellular 
signal-regulated kinases 1 and 2; WM, wortmannin; DMSO, dimethyl sulfoxide; Baf A1, bafilomycin A1.
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examined the expression levels of beclin 1 and LC3-II when 
MCF7 and MDA-MB-231 cells were treated with Danu alone 
or in combination with SB202190 or U0126, by Western 
blotting assay. Treatment of cells with 0.5 µM Danu in com-
bination with 10 µM SB202190 remarkably decreased the 
expression level of beclin 1 by 25.5% in MCF7 cells (P0.05 
by one-way ANOVA;  Figure 16A and B); however, there 
was no significant change in MDA- MB-231 cells, compared 
to the control cells treated with Danu alone (P0.05 by 
one-way ANOVA; Figure 16A and B). Treating cells with 
0.5 µM Danu plus 10 µM U0126 did not significantly 
change the expression level of beclin 1 in MCF7 and MDA-
MB-231 cells (P0.05 by one-way ANOVA; Figure 16A 
and B). Moreover, incubation of cells with 0.5 µM Danu 
plus 10 µM SB202190 significantly decreased the level 
of LC3-II by 38.7% in MCF7 cells (P0.01 by  one-way 
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Figure 16 Effects of specific p38 MAPK and Erk1/2 inhibitors on Danu-induced autophagy in MCF7 cells and MDA-MB-231 cells. 
Notes: cells were pretreated with sB202190 (10 µM) or U0126 (10 µM) for 30 minutes, 0.5 µM Danu was added for further incubation of 24 hours, and cells were harvested. 
The percentage of autophagic MCF7 and MDA-MB-231 cells was examined by flow cytometry with Cyto-ID® as the green stain for autophagic vacuoles. (A) Flow cytometric 
dot plots showing the autophagic McF7 and MDa-MB-23 cells, and (B) bar graphs showing the percentage of autophagic McF7 and MDa-MB-231 cells. Data are expressed 
as the mean ± sD of three independent experiments. *P0.05; **P0.01; and ***P0.001 by one-way anOVa.
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ANOVA; Figure 16A and B), there was no significant change 
in MDA-MB-231 cells, compared to the control cells treated 
with Danu alone (P0.05 by one-way ANOVA; Figure 16A 
and B). Treatment of cells with 0.5 µM Danu plus 10 µM 
U0126 decreased the level of LC3-II by 52.4% but increased 
the level of LC3-II 1.4-fold in MCF7 cells, compared to the 
control cells treated with Danu alone (P0.001 by one-way 
ANOVA; Figure 16A and B).
Furthermore, SB202190 completely blocked p38 
MAPK activation, and U0126 completely blocked Erk1/2 
activation. Treatment of cells with 0.5 µM Danu plus 
10 µM SB202190 significantly decreased the ratio of p-p38 
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Figure 17 effects of p38 MaPK and erk1/2 inhibitors on the activation of p38 MaPK, erk1/2, and akt, and the expression of beclin 1 and lc3-i and -ii in McF7 and MDa-MB-231 cells. 
Notes: McF7 and MDa-MB-231 cells were pretreated with sB20290 (10 µM) or U0126 (0 µM) for 30 minutes before adding 0.5 µM Danu for further incubation of 24 hours. 
cells were then harvested and protein samples were subjected to Western blotting assay. (A) representative blots of p-p38 MaPK, p38 MaPK, p-erk1/2, erk1/2, p-akt, akt, 
beclin 1, and lc3-i and ii in McF7 and MDa-MB-231 cells, and (B) bar graphs showing the ratio of p-p38 MaPK/p38 MaPK, p-erk1/2/erk1/2, and p-akt/akt in McF7 and 
MDa-MB-231 cells. β-actin was used as the internal control. Data are expressed as the mean ± sD of three independent experiments. *P0.05; **P0.01; and ***P0.001 by 
one-way anOVa.
Abbreviations: Danu, danusertib; sD, standard deviation; anOVa, analysis of variance; p, phosphorylated; MaPK, mitogen-activated protein kinase; erk/2, extracellular 
signal-regulated kinases 1 and 2; akt, protein kinase B; lc3, microtubule-associated protein 1a/1 B-light chain 3; DMsO, dimethyl sulfoxide.
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MAPK over total p38 MAPK by 92.2% in MCF7 cells 
(P0.001 by one-way ANOVA; Figure 17A and B), and 
there was a 52.9% decrease in the ratio of p-p38 MAPK 
over total p38 MAPK in MDA-MB-231 cells, compared 
to the control cells treated with Danu alone (P0.01 by 
one-way ANOVA; Figure 17A and B). Treating cells with 
0.5 µM Danu plus 10 µM U0126 significantly increased the 
ratio of p-p38 MAPK/p38 MAPK 2.2-fold in MCF7 cells 
(P0.001 by one-way ANOVA; Figure 17A and B), and 
there was a 52.9% decrease in the ratio of p-p38 MAPK 
over p38 MAPK in MDA-MB-231 cells, compared to the 
control cells treated with Danu alone (P0.01 by one-way 
ANOVA; Figure 17A and B). Moreover, treatment of cells 
with 0.5 µM Danu plus 10 µM SB202190 increased the 
ratio of p-Erk1/2 over total Erk1/2 2.6-fold in both MCF7 
and MDA-MB-231 cells, compared to the control cells 
treated with Danu alone (P0.001 by one-way ANOVA; 
Figure 17A and B). Incubation of cells with 0.5 µM Danu 
in combination with 10 µM U0126 significantly decreased 
the ratio of p-Erk1/2 over total Erk1/2 81.6% and 69.7% 
in MCF7 cells and MDA-MB-231 cells, respectively, com-
pared to the control cells treated with Danu alone (P0.001 
by one-way ANOVA; Figure 17A and B). Treatment of 
cells with 10 µM SB202190 alone significantly decreased 
the ratio of p-Akt at Ser473 over Akt 96.4% and 91.1% in 
MCF7 cells and MDA-MB-231 cells, respectively, com-
pared to the control cells treated with DMSO only (P0.001 
by one-way ANOVA; Figure 17A and B); exposure of cells 
to 10 µM U0126 significantly decreased the p-Akt/Akt ratio 
85.4% and 75.5% in MCF7 cells and MDA-MB-231 cells, 
respectively, compared to the control cells treated with 
DMSO only (P0.001 by one-way ANOVA; Figure 17A 
and B). However, there was no significant change in the 
p-Akt/Akt ratio when MCF7 cells and MDA-MB-231 cells 
were treated with 0.5 µM Danu plus 10 µM SB202190, and 
there was also no significant change when MCF7 cells were 
treated with 0.5 µM Danu plus 10 µM U0126, compared 
to the control cells treated with Danu alone (P0.05 by 
one-way ANOVA; Figure 17A and B). However, treat-
ment of cells with 0.5 µM Danu combined with 10 µM 
U0126 significantly increased the ratio of p-Akt over total 
Akt in MDA-MB-231 cells by 2.1-fold, compared to the 
control cells treated with Danu alone (P0.001 by one-way 
ANOVA; Figure 17A and B). 
To further confirm the roles of p38 MAPK and Erk1/2 in 
Danu-induced autophagy, p38 MAPK- and Erk1/2-specific 
siRNAs were used to knock down the gene expression of 
p38 MAPK or Erk1/2. Transfection of MCF-7 cells with p38 
MAPK siRNA downregulated the level of Danu-induced 
phosphorylation of p38 MAPK, and increased LC3-II level 
compared with parental or nonspecific siRNA-transfected 
control cells. Compared to MCF-7 cells transfected with 
control siRNA, transfecting p38 MAPK siRNA significantly 
decreased by 50% in the p-p38 MAPK/p38 MAPK ratio, 
and transfecting Erk1/2 siRNA significantly decreased by 
85.6% in the ratio of p-Erk1/2 over total Erk1/2 (P0.001 by 
one-way ANOVA; Figure 18A and B). After transfection of 
MCF-7 cells with p38 MAPK siRNA, we found that the ratio 
of p-Akt over total Akt and the level of LC3-II were increased 
2.2- and 3.6-fold compared to transfecting control siRNA, 
respectively (P0.001 by one-way ANOVA; Figure 18A 
and B); however, there were no significant changes in the 
p-Erk1/2:Erk1/2 ratio and the level of beclin 1 compared to 
transfecting control siRNA (P0.05 by one-way ANOVA; 
Figure 18A and B). After transfection of MCF-7 cells with 
Erk1/2 siRNA, we observed that the level of LC3-II was 
increased 1.5-fold compared to the cells transfected with the 
control siRNA (P0.001 by one-way ANOVA; Figure 18A 
and B); however, there were no significant changes in the 
ratios of p-p38 MAPK over total p38 MAPK, and p-Akt over 
total Akt, and in the level of beclin 1 compared to the cells 
transfected with the control siRNA (P0.05 by one-way 
ANOVA; Figure 18A and B). 
Furthermore, after transfection of MCF-7 cells with p38 
MAPK siRNA and 0.5 µM Danu treatment, we found that the 
level of LC3-II was markedly increased 3.9-fold compared 
to Danu treated siRNA transfection cells (P0.001 by one-
way ANOVA; Figure 18A and B); however, there were no 
significant changes in the ratios of p-p38 MAPK over total 
p38 MAPK, p-Erk1/2 over total Erk1/2, and p-Akt over 
total Akt, and no significant change in the level of beclin 1 
compared to transfecting control siRNA with 0.5 µM Danu 
(P0.05 by one-way ANOVA; Figure 18A and B). After 
transfection of MCF-7 cells with Erk1/2 siRNA transfection 
cells treated with 0.5 µM Danu, we observed that the ratio of 
p-p38 MAPK over total p38 MAPK and the level of LC3-II 
were increased 1.8- and 1.5-fold, respectively, compared to 
transfecting control siRNA with 0.5 µM Danu (P0.001 
by one-way ANOVA; Figure 18A and B); however, there 
were no significant changes in the ratio of p-Akt over total 
Akt and the level of beclin 1, compared to transfecting 
control siRNA (P0.05 by one-way ANOVA; Figure 18A 
and B); in addition, the ratio of p-Erk1/2 over total Erk1/2 
was decreased by 83.5% compared to transfecting control 
siRNA (P0.001 by one-way ANOVA; Figure 18A and B). 
These results have further confirmed that p38 MAPK and 
Erk1/2 signaling pathways are involved in Danu-induced 
autophagy.
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Figure 19 Danu concentration-dependently inhibits the expression of selected eMT markers in McF7 and MDa-MB-231 cells. 
Notes: cells treated with Danu at 0.01, 0.1 and 0.5 µM for 24 hours and protein samples were subjected to Western blotting assay. (A) representative blots of e-cadherin, 
n-cadherin, snail, slug, TcF8/ZeB1, vimentin, β-catenin, and ZO-1 in McF7 and MDa-MB-231 cells, and (B) bar graphs showing the levels of e-cadherin, n-cadherin, 
snail, slug, TcF8/ZeB1, vimentin, β-catenin, and ZO-1 in McF7 and MDa-MB-231 cells. β-actin was used as the internal control. Data represent the mean ± sD of three 
independent experiments. *P0.05; **P0.01; and ***P0.001 by one-way anOVa.
Abbreviations: Danu, danusertib; conc, concentration; sD, standard deviation; anOVa, analysis of variance; eMT, epithelial-to-mesenchymal transition; TcF8/ZeB1, zinc 
finger E-box-binding homeobox 1; ZO-1, zona occludens protein 1.
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Danu inhibits eMT in McF7 and MDa-
MB-231 cells
EMT is a critical process involving the initiation, growth, 
invasion, and metastasis of cancer.24 Herein, we examined the 
effect of Danu treatment on EMT-associated markers in MCF7 
and MDA-MB-231 cells using the Western blotting assay. As 
shown in Figure 19A and B, incubation of MCF-7 cells with 
Danu resulted in a remarkable increase in the expression level 
of E-cadherin and a decrease in the expression level of N-cad-
herin. There was a 1.3-fold increase in the expression of E-cad-
herin when treated with 0.5 µM Danu for 24 hours, whereas 
0.01, 0.1, and 0.5 µM Danu suppressed the expression level of 
N-cadherin 41.1%, 58.9%, and 56.1%, respectively (P0.001 
by one-way ANOVA; Figure 19A and B). Consequently, 
with increasing concentrations of PLB, an increased ratio of 
E-cadherin over N-cadherin was observed. The E-cadherin/ 
N-cadherin ratio was increased from 0.37 at basal level to 0.77 
and 1.13, when MCF7 cells were treated with Danu at 0.1 and 
0.5 µM Danu for 24 hours, respectively (P0.001 by one-
way ANOVA; Figure 19A and B). In MDA-MB-231 cells, 
there was a 1.5-fold increase in the expression of E-cadherin 
when cells were treated with 0.5 µM Danu for 24 hours. 
Meanwhile, 0.1 and 0.5 µM Danu decreased the expression 
level of N-cadherin by 32.3% and 25.8%, respectively. The 
E-cadherin/N-cadherin ratio was increased from 1.5 to 2.8 and 
3.0, when MDA-MB-231 cells were treated with Danu at 0.1 
and 0.5 µM for 24 hours, respectively (P0.01 by one-way 
ANOVA; Figure 19A and B). 
In order to further examine the effect of Danu on EMT 
in MCF7 and MDA-MB-231 cells, we tested the expression 
levels of several key regulators of E-cadherin. Snail and 
slug (both zinc finger transcriptional factors), together with 
TCF8/ZEB1, are suppressors of E-cadherin in EMT.26 In 
addition, snail blocks the cell cycle and confers resistance to 
cell death, and slug protects damaged cells from apoptosis 
by repressing p53-induced transcription of the pro-apoptotic 
Bcl-2 family protein PUMA. Danu significantly reduced 
the expression level of snail and slug in both cell lines. 
In MCF7 cells, 24-hour Danu treatment at 0.01, 0.1, and 
0.5 µM significantly suppressed the expression level of snail 
by 35.9%, 50.5%, and 76.6%, and inhibited the expression 
of slug by 13.9%, 45.2%, and 72.3%, respectively (P0.05 
by one-way ANOVA; Figure 19A and B). In MDA-MB-231 
cells, treatment with 0.01, 0.1, and 0.5 µM Danu suppressed 
the expression level of snail by 19.1%, 48.3%, and 44.8%, 
respectively. Treatment of cells with 0.1 and 0.5 µM Danu for 
24 hours reduced expression level of slug by 27.9% and 35.1%, 
respectively (P0.01 by one-way ANOVA; Figure 19A and 
B). Furthermore, Danu induced a marked reduction in the 
expression level of TCF8/ZEB1 in MCF7 and MDA-MB-231 
cells. In MCF7 cells, 0.1 and 0.5 µM Danu significantly sup-
pressed the expression level of TCF8/ZEB1 by 14% and 29%, 
respectively. Similarly, there was a 31.6%, 52.6%, and 42.1% 
reduction in the expression of TCF8/ZEB1 in MDA-MB-231 
cells treated with 0.01, 0.1, and 0.5 µM Danu, respectively 
(P0.05  by one-way ANOVA; Figure 19A and B). Vimentin 
is a type III intermediate filament protein that is expressed in 
mesenchymal cells. β-catenin can act as an integral component 
of a protein complex in adherens junctions, which help cells 
maintain epithelial layers, and β-catenin participates in the Wnt 
signaling pathway as a downstream target.26 Treatment of cells 
with 0.01, 0.1, and 0.5 µM Danu significantly suppressed the 
expression level of vimentin by 25.0%, 40.0%, and 55.0%, 
respectively, in MCF7 cells. Danu at 0.1 and 0.5 µM reduced 
vimentin level by 28.4% and 49.0%,  respectively, in MDA-
MB-231 cells (P0.01 by one-way ANOVA; Figure 19A and 
B). There was a significant reduction in the expression level 
of β-catenin in both cell lines treated with Danu. Treatment of 
cells with Danu at 0.01, 0.1, and 0.5 µM decreased the expres-
sion level of β-catenin by 35.6%, 40.1%, and 43.9% in MCF7 
cells, respectively, and 0.1 and 0.5 µM Danu reduced β-catenin 
expression by 22.4% and 25.8% in MDA-MB-231 cells, respec-
tively (P0.01 by one-way ANOVA; Figure 19A and B). 
Finally, the expression of ZO-1 was examined in MCF7 and 
MDA-MB-231 cells exposed to Danu. Treatment of MCF7 
cells with 0.1 and 0.5 µM Danu for 24 hours increased the 
expression of ZO-1 1.5- and 1.3-fold, respectively, and treat-
ment with 0.01, 0.1, and 0.5 µM Danu resulted in a 1.4-, 1.6-, 
and 1.9-fold increase in the expression level of ZO-1 in MDA-
MB-231 cells, respectively (P0.05 by one-way ANOVA; 
Figure 19A and B).
Furthermore, we examined the effect of Danu on the 
expression of selected EMT markers in MCF7 and MDA-
MB-231 cells over 72 hours. There was a significantly inhibi-
tory effect of Danu on EMT in both cells. In comparison 
to the control cells, treatment of MCF7 cells with 0.5 µM 
Danu for 4, 8, 12, 24, 48, and 72 hours increased the 
expression of E-cadherin by 1.7-, 2.2-, 3.2-, 2.8-, 2.6-, and 
2.0-fold, respectively, while the expression of N-cadherin 
was decreased by 40.2% and 44.1% after 48 and 72 hours, 
respectively, which in turn led to a significant increase in 
the ratio of E-cadherin over N-cadherin (P0.05 by one-
way ANOVA; Figure 20A and B). The expression of snail 
was significantly decreased by 41.3% with the 0.5 µM 
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Figure 20 Danu modulates the expression level of selected eMT markers in McF7 and MDa-MB-231 cells in a time-dependent manner. 
Notes: cells treated with 0.5 µM Danu for 4 to 72 hours and protein samples were subjected to Western blotting assay. (A) representative blots show the levels of 
e-cadherin, n-cadherin, snail, slug, TcF8/ZeB1, vimentin, β-catenin, and ZO-1 in McF7 and MDa-MB-231 cells, and (B) bar graphs show the levels of e-cadherin, n-cadherin, 
snail, slug, TcF8/ZeB1, vimentin, β-catenin, and ZO-1 in McF7 and MDa-MB-231 cells. β-actin was used as the internal control. Data are represented as the mean ± sD of 
three independent experiments. *P0.05; **P0.01; and ***P0.001 by one-way anOVa.
Abbreviations: Danu, danusertib; SD, standard deviation; ANOVA, analysis of variance; hr, hour; TCF8/ZEB1, zinc finger E-box-binding homeobox 1; ZO-1, zona occludens 
protein 1.
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Danu treatment for 72 hours, and the expression of slug 
was reduced by 37.5%, 44.0%, 54.2%, and 68.9% with the 
0.5 µM Danu treatment for 12, 24, 48, and 72 hours, respec-
tively (P0.05 by one-way ANOVA; Figure 20A and B). 
The expression of vimentin was significantly decreased 
29.1%, 39.9%, 36.8%, and 38.4% with the 0.5 µM Danu 
treatment for 4, 24, 48, and 72 hours, respectively. More-
over, the expression of β-catenin was reduced by 60.0%, 
71.8%, and 59.7% with the 0.5 µM Danu treatment for 
24, 48, and 72 hours, respectively (P0.05 by one-way 
ANOVA; Figure 20A and B). The expression of TCF8/ZEB1 
was significantly decreased by 22.6%, 23.5%, 45.5%, and 
81.7% with the 0.5 µM Danu treatment for 4, 24, 48, and 
72 hours, respectively. However, the expression of ZO-1 
was increased by 1.6- and 2.4-fold with the 0.5 µM Danu 
treatment for 48 and 72 hours, respectively (P0.05  by one-
way ANOVA; Figure 20A and B). In MDA-MB-231 cells, 
incubation with 0.5 µM Danu for 12 and 72 hours led to a 
1.6- and 1.5-fold increase in the expression of E-cadherin, 
respectively; and incubation of 0.5 µM Danu for 4, 24, 48, 
and 72 hours resulted in a 40.8%, 50.5%, 43.0%, and 61.8% 
reduction in the expression of N-cadherin compared to the 
control cells. Consequently, it led to an increase in the ratio 
of E-cadherin over N-cadherin. The expression of snail 
was decreased by 25.2%, 72.3%, and 84.3%, respectively, 
with the 0.5 µM Danu treatment for 24, 48, and 72 hours 
(P0.05;  by one-way ANOVA Figure 20A and B). How-
ever, the expression of slug did not significantly change 
with the 0.5 µM Danu treatment over 72 hours (P0.05 
by one-way ANOVA; Figure 20A and B). The expression 
of vimentin was significantly decreased by 42.6%, 65.7%, 
and 62.8% with the 0.5 µM Danu treatment for 4, 8, and 
12 hours, respectively. The expression of β-catenin was 
reduced by 41.4%, 47.2%, and 59.3% with the 0.5 µM Danu 
treatment for 12, 24, and 72 hours, respectively (P0.05  by 
one-way ANOVA; Figure 20A and B). The expression of 
TCF8/ZEB1 was significantly decreased by 70.4%, 74.8%, 
74.9%, and 86.0% with the 0.5 µM Danu treatment for 8, 
24, 48, and 72 hours, respectively. The expression of ZO-1 
was increased by 2.9- and 2.3-fold with the 0.5 µM Danu 
treatment for 48 and 72 hours, respectively (P0.05  by 
one-way ANOVA; Figure 20A and B). Taken together, 
Danu exhibits a potent inhibitory effect on EMT in MCF7 
and MDA-MB-231 cells. 
Discussion
Several Aurora kinase inhibitors have been tested in breast 
cancer preclinically in the last couple of years, indicating 
Aurora kinases are promising therapeutic targets for breast 
cancer. In this study, we investigated the anti-proliferative 
and anti-invasive effects of Danu on nonmalignant and 
malignant breast cell lines. The Aurora family comprises 
three related kinases (AURKA/B/C) that share the highest 
degree of sequence homology in their catalytic domains.27,28 
Overexpression of Aurora kinases has been demonstrated in a 
variety of human malignancies including that of breast cancer, 
and the overexpression has been shown to induce chromo-
somal instability, resulting in aneuploidy.29,30 Notably, aneu-
ploidy is the salient feature of most cancer cells and is closely 
correlated with mammalian cell transformation.31 Recently, 
there are a number of Aurora kinase inhibitors that have been 
discovered and are under preclinical or clinical development 
at different stages. Danu, a small adenosine triphosphate 
competitive molecule that inhibits AURKA/B/C, has entered 
Phase II clinical trials for patients with solid tumors.19 Danu 
has strong activity on AURKB, as determined by inhibition 
of its substrate histone H3 in position Ser10 and also on 
AURKA, as determined by inhibition of autophosphorylation 
in position Thr288.32,33 It has been shown that Danu inhibits 
the proliferation of hepatocellular carcinoma and pancreatic 
cancer cells via inducing cell division failure and resulting 
in polyploidy.34,35 In the present study, our results show that 
Danu inhibits proliferation of cells and induces G
2
/M arrest, 
apoptosis, and autophagy in nonmalignant and malignant 
breast cell lines via p38 MAPK/Erk1/2–Akt/mTOR mediated 
signaling pathways. Additionally, Danu also inhibits EMT 
in malignant breast cell lines. 
Cell cycle control is a dominant regulatory mechanism in 
cell growth, involving a number of functional proteins and 
related signaling pathways, including CDK1 and 2, cyclin 
B1, p21 Wafl/Cip1, and p27 Kipl. Targeting the cell cycle 
has been proposed to be a promising strategy for cancer 
treatment, and many cytotoxic agents and/or DNA-damaging 
agents have been developed which are able to arrest the 
cell cycle at the G
0
/G
1
, S, or G
2
/M phase, and then induce 
cell apoptosis.36 G
2
/M transition is controlled by CDC2, 
also known as CDK1, which partners with cyclin B1. CDC 
family proteins and cyclin complexes play a critical role 
in the regulation of G
2
/M transition. G
2
/M arrest is closely 
regulated via the activation and deactivation of CDC family 
proteins and cyclin complexes. In the present study, we found 
that Danu concentration-dependently arrested MCF10A, 
MCF7, and MDA-MB-231 cells in the G
2
/M phase. We 
further explored the effect of Danu on the key regulators 
in cell cycle checkpoints including CDC2/CDK1, CDK2, 
and cyclin B1 in all cells. The CDC2–cyclin B1 complex is 
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pivotal in regulating the G
2
/M phase transition and mitosis. 
We observed a significant decrease in the expression level 
of cyclin B1 and CDC2 in MCF10A, MCF7, and MDA-MB-
231 cells treated with Danu, providing an explanation for the 
effect of Danu on G
2
/M phase arrest in MCF10A, MCF7, 
and MDA-MB-231 cells.
Furthermore, cell cycle progression is also tightly regu-
lated by the relative balance between the cellular concentra-
tions of cyclin-dependent kinase inhibitors, such as the Cip/
Kip family. The Cip/Kip family, including p21 Waf1/Cip1 
and p27 Kipl, binds to cyclin–CDK complexes, preventing 
the kinase activation and blocking the progression of the cell 
cycle at the G
2
/M phases.37 Moreover, it has been reported 
that p21 Waf1/Cip1, a cyclin-dependent kinase inhibitor 
regulated by p53, can bind to the CDK1/CDC2–cyclin B1 
complex, thereby inducing cell cycle arrest. We observed 
that the expression of p53, p27 Kip1, and p21 Waf1/Cip1 
was concentration- and time-dependently increased in 
MCF10A, MCF7, and MDA-MB-231 cells treated with 
Danu, which probably contributes to the inhibitory effect 
of Danu on cell proliferation, and the inducing effect on 
cell cycle arrest in nonmalignant and malignant breast cells. 
These results indicate that upregulation of p53, p21 Waf1/
Cip1, and p27 Kip1 expression, and the suppression of CDK2 
and cyclin B1 by Danu may result in G
2
/M phase arrest in 
human breast cells.
Apoptosis not only plays a crucial role in tissue develop-
ment and homeostasis but is also involved in a wide range 
of pathologies.38 Apoptotic cells have morphologically 
defined nuclear features of chromatin condensation and DNA 
 fragmentation.39 The apoptotic process occurs via two distinct 
signaling pathways, known as the tumor necrosis factor/
Fas-receptor, and mitochondria-mediated pathways, with 
the involvement of the caspase family, including  caspases 3, 
6, 7, 8, and 9.40,41 In the present study, we observed a concen-
tration-dependent apoptosis induced by Danu in MCF10A, 
MCF7, and MDA-MB-231 cells. Anti-apoptotic members of 
Bcl-2 can be inhibited by post-translational modification and/
or by increased expression of PUMA, which is an essential reg-
ulator of p53-mediated cell apoptosis.42 In our study, we found 
that the expression level of cleaved caspase 9 was significantly 
increased after Danu treatment, which subsequently activated 
caspase 3. Activated caspase 3, in turn, induced apoptosis with 
a decrease in Bcl-2 level. Moreover, we noted a concentration-
dependent increase in the expression level of PUMA and Bax 
in MCF10A, MCF7, and MDA-MB-231 cells. These results 
indicate that Danu induces mitochondria-dependent apoptosis 
in nonmalignant and malignant breast cells.
Autophagy is a primary, morphologically distinctive 
mode of programmed cell death, which is an important 
process involving the engulfment and degradation of nones-
sential or abnormal cellular organelles and proteins in living 
cells.43 The role of autophagy in cancer cell death is still 
controversial. Genetic evidence indicates that autophagy can 
suppress tumor growth, but it also can support the survival 
of established tumors under stress conditions.44,45 However, 
increasing evidence shows that targeting autophagy is a 
promising strategy for the treatment of breast cancer,46–49 
and induction of autophagy has been tested for a potential 
therapeutic strategy to treat cancer.50 Beclin 1 and LC3 are 
two specific markers of cell autophagy, and both of them 
are strongly involved in the autophagic process, especially 
in its early stages. Beclin 1, initially isolated as a Bcl-2- 
binding protein,
 
was the first human protein is shown to be 
indispensable for autophagy. Beclin 1 and Vps34 (class III 
PI3K) form a complex in charge of autophagic nucleation 
in mammals. Beclin 1 promotes autophagy and inhibits 
proliferation of cancer cells by forming and activating the 
autophagy-promoting complex beclin 1–Vps34, and the sup-
pression of beclin 1 expression impairs autophagy.51 LC3, 
associated with the formation of the autophagic vacuole, 
is currently considered as a specific molecular marker for 
autophagosomes in mammals. LC3 proteins can be divided 
into two forms: LC3-I (18 kDa) and LC3-II (16 kDa). The 
amount of LC3-II correlates with the extent of autophago-
some formation, and it is an autophagosomal marker.52 In 
our study, the induction of autophagy was supported by 
the following observations. First, using flow cytometric 
analysis, we found Danu treatment of MCF10A, MCF7, 
and MDA-MB-231 cells induced remarkable autophagy in 
concentration- and time-dependent manners. Second, there 
was a striking increase in the expression level of beclin 1 
and LC3-II in MCF10A, MCF7, and MDA-MB-231 cells 
treated with Danu in concentration- and time-dependent 
manners, as expressed in Western blotting. These results 
indicate that Danu can induce autophagy in breast cells, 
and nonmalignant cells are less sensitive to Danu-induced 
autophagy than malignant MCF7 and MDA-MB-231 cells. 
Furthermore, we also found that Danu significantly induced 
p38 MAPK and Erk1/2 activation; on the contrary, it down-
regulated the activation of Akt and mTOR.
MAPK family members, including JNK, Erk1/2, and p38 
MAPK have been reported to be involved in autophagy.53 
p38 MAPK is an important stress kinase involved in a num-
ber of cellular processes, including inflammation response, 
cell growth and differentiation, cell cycle progression, and 
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cell death. In the present study, we have observed that 
Danu treatment significantly increased the phosphoryla-
tion of p38 MAPK and Erk1/2 in MCF10A, MCF7, and 
MDA-MB-231 cells in concentration- and time-dependent 
manners. With increasing concentrations or sustained time 
exposed to Danu, an increasing amount of phosphorylated 
p38 MAPK and Erk1/2, and highly accumulated LC3-II were 
observed. Thus, the results demonstrate that the activation 
of p38 MAPK and Erk1/2 is involved in Danu-induced 
autophagy. We further confirmed our findings via pharma-
cological inhibitors of autophagy. WM, an inhibitor for the 
sequestration step of autophagosome, completely blocked 
Danu-induced p38 MAPK and Erk1/2 activation in MCF7 
and MDA-MB-231 cells. These observations suggest that 
p38 MAPK and Erk1/2 regulate autophagosome formation 
at the sequestration step. It is noteworthy that SB202190 
(an inhibitor of p38 MAPK) downregulates Danu-induced 
activation of Erk1/2, resulting in a reduction in LC3-II con-
version in MCF7 and MDA-MB-231 cells. On the contrary, 
knockdown of p38 MAPK using p38 MAPK siRNA inhibited 
Danu-induced phosphorylation of Erk1/2, and eventually 
caused an accumulation of LC3-II. On the other hand, 
U0126 (an inhibitor of Erk1/2) also inhibited Danu-induced 
activation of p-p38 MAPK expression level, and caused the 
reduction of LC3-II conversion in MCF7 cells. Knockdown 
of the Erk1/2 gene using Erk1/2 siRNA aided Danu-induced 
increases in p-p38 MAPK expression level, but that still led 
to an accumulation of LC3-II in MCF7 cells. These observa-
tions further confirmed that p38 MAPK and Erk1/2 played 
important roles in Danu-induced autophagy.
To understand the underlying mechanism for the 
autophagy-inducing effect of Danu, we further investigated 
the classic mTOR-signaling pathway. mTOR is an atypical 
serine/threonine kinase that is present in two distinct com-
plexes: mTOR complex 1 (mTORC1) and mTOR complex 2 
(mTORC2). mTOR plays a key role in cell growth, 
autophagic cell death, and homeostasis. mTOR is phos-
phorylated at Ser2448 via the PI3K/Akt signaling pathway, 
and is autophosphorylated at Ser248. Inhibition of mTOR 
promotes the dissociation of mTOR from the complex of 
Atg13 with ULK1 and ULK2. This releases ULK1/2 to 
activate FIP200, a protein critical for autophagosome for-
mation and autophagy initiation; as an upstream effector of 
mTOR, Akt can activate mTOR via direct phosphorylation 
and inhibition of tuberous sclerosis complex 2 (TSC2), which 
is a negative regulator of mTOR.54 In the present study, 
Danu significantly reduced the phosphorylation of mTOR at 
Ser2448 and Akt at Ser473 in both MCF7 and MDA-MB-231 
cells, in a  concentration-dependent manner. With increasing 
concentrations of Danu, a decreased phosphorylation level 
of mTOR and Akt was observed. In addition, there was a 
time-dependent decrease in the phosphorylation level of 
mTOR and Akt in MCF7 and MDA-MB-231 cells treated 
with Danu. However, the total Akt and total mTOR were 
not significantly changed when MCF7 and MDA-MB-231 
cells were treated with Danu. These results suggest that Danu 
causes a downregulation in the phosphorylation of Akt and 
mTOR, contributing to the autophagy-inducing effect of 
Danu in MCF7 and MDA-MB-231 cells. 
We further provided evidence about the existence of cross-
talk among the p38 MAPK, Erk1/2, and mTOR signaling 
pathways in the process of Danu-induced autophagy. The 
possible role of p38 MAPK in the regulation of autophagy 
has been reported, in that activation of p38 MAPK led to 
an inhibition of autophagy.55 However, a subsequent study 
presented an opposite finding that activation of p38 MAPK 
caused an induction of autophagy.56 Moreover, it has been 
reported that a novel cell type-specific role of p38 MAPK in 
the control of autophagy and cell death in colorectal cancer 
cells exists.57 However, the possible molecular mechanisms 
that link p38 MAPK to autophagy are not yet known. Our 
studies have demonstrated that Danu induced activation of 
p38 MAPK and Erk1/2, and decreased activation of Akt 
and mTOR. To confirm p38 MAPK and Erk1/2 induced 
autophagy via the Akt/mTOR signaling pathway, we silenced 
p38 MAPK and Erk1/2 using p38 MAPK siRNA and Erk1/2 
siRNA in MCF7 cells and tested the alteration in the phospho-
rylation of Akt. We found that MCF7 cells transfected with 
p38 MAPK siRNA downregulated the level of Danu-induced 
p-p38 MAPK, but upregulated the activation of Akt, leading 
to LC3-II accumulation. However, transfection of MCF7 cells 
with Erk1/2 siRNA did not elicit a marked activation of Akt, 
but effectively promoted LC3 conversion. Furthermore, we 
observed the effect of p38 MAPK inhibitor SB202190 and 
Erk1/2 inhibitor U0126 on Danu-inhibited phosphorylation of 
Akt in MCF7 and MDA-MB-231 cells. SB202190 completely 
inhibited the activation of Akt, and U0126 also inhibited the 
activation of Akt in both cell lines. Taken together, these 
results demonstrate that p38 MAPK and Erk1/2 signaling 
pathways are involved in the autophagy-inducing effect of 
Danu in MCF7 and MDA-MB-231 cells. 
EMT, a physiological process essential during embryonic 
development, is characterized by a loss of cell polarity and 
cell–cell adhesion, and gain active cell motility when epi-
thelial cells convert to a mesenchymal cell phenotype.58 In 
the metastasis of cancer, the increased motility and invasive 
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behavior of cancer cells underwent EMT, due to the loss 
of adhesion molecules such as E-cadherin, and the gain of 
mesenchymal proteins such as N-cadherin and vimentin.59 In 
the clinic, breast cancer patient mortality is mainly attributed 
to the spread of cancerous cells to areas outside the mam-
mary gland and the inadequate strategies to effectively block 
progression to metastasis, in which EMT plays a critical 
role.24 In primary breast cancer cells, reduction or loss of 
expression of E-cadherin and β-catenin were observed.24 In 
the present study, Danu significantly increased the ratio of 
E-cadherin over N-cadherin, which would result in an EMT 
inhibition in breast cancer. Furthermore, Danu suppressed 
the expression of snail, slug, and TCF8/ZEB1 in MCF7 and 
MDA-MB-231 cells. Snail and slug are master regulators of 
EMT, downregulating E-cadherin by silencing gene expres-
sion. TCF8/ZEB1 functions as an activator of the EMT pro-
cess through downregulation of epithelial genes. Moreover, 
Danu significantly increased the expression level of ZO-1, 
but decreased the expression level of vimentin and β-catenin. 
ZO-1 is required for tight junction formation and function 
involving the regulation of paracellular permeability, and 
the maintenance of cell polarity, blocking the movement of 
transmembrane proteins between the apical and the basolat-
eral cell surfaces,60 whereas vimentin is a marker expressed 
in mesenchymal cells. β-catenin can act as an integral com-
ponent of a protein complex in adherens junctions that helps 
cells maintain epithelial layers, and β-catenin participates in 
the Wnt signaling pathway as a downstream target.24 Similar 
data were obtained in a time-dependent manner in MCF7 
and MDA-M-231 cells. These results indicated that Danu 
inhibited EMT in breast cancer cells.
Conclusion
In summary, the present study showed that Danu  inhibited 
cell proliferation, induced G
2
/M arrest, activated the 
 mitochondria-dependent apoptotic pathway, promoted 
autophagy, and suppressed EMT in MCF7 and MDA-MB-
231 cells. Danu induced autophagy via p38 MAPK/Erk1/2–
Akt/mTOR signaling pathways in MCF7 and MDA-MB-231 
cells. These results indicate that Danu may represent a new 
anticancer drug that can kill breast cancer cells and prevent 
EMT. More studies are needed to fully elucidate the underly-
ing mechanisms, efficacy, and safety of Danu in the treatment 
of human breast cancer.
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